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Abstract:
Development of Polymeric Carriers for the Treatment of Acute Kidney Injury
Yi Chen, Ph.D.
University of Nebraska Medical Center, 2018
Supervisor: David Oupický, Ph.D.
Acute kidney injury (AKI) is a major kidney disease associated with high mortality
and morbidity. Long-term AKI may lead to chronic kidney disease and end-stage renal
disease. Several clinical trials failed due to lack of efficacy and undesired side effects.
Studies showed that macromolecular delivery systems would be a promising method to
target kidney, however, little is known about how physicochemical properties affects the
polymers deposition in ischemia-reperfusion (I/R) AKI.
Gene therapy has been well studied as a promising therapeutic agent for several
diseases, including cancer and AKI. Although small interfering RNA (siRNA) has been
commonly used to treat AKI through hydrodynamic injection, this method has some
disadvantages.
The expression of CXCR4 increases in response to AKI. Emerging evidence shows
that CXCR4/SDF-1 axis is implicated in regulating trafficking and invasion of
inflammatory cells in the injured kidneys. The inhibition of the axis appears to exert
beneficial therapeutic effect in AKI.
First, to understand how physicochemical properties affects renal accumulation in
AKI, we synthesized a panel of 9 fluorescently labeled polymers with a range of size and

different net charge. By testing biodistribution in unilateral I/R animal model, we found
negatively charged pMAA-5 and neutral pHPMA-36 had greatest potential for
accumulating in I/R kidneys as compared with sham-operated kidneys. The polymers
passed through glomerulus and sustained in proximal tubular cells for up to 24 hours
after injection. We also confirmed the consistency of bilateral and unilateral I/R animal
model by confirming biodistribution of pAPMA-30 and pHPMA-16 in bilateral I/R animal
model. This study demonstrated for the first time that polymers with specific physical
characteristics exhibit promising enhanced ability to accumulate in AKI kidney.
Second, to explore the potential of CXCR4/SDF-1 axis in the treatment of AKI, we
formulated polyplexes with our previously synthesized polymeric CXCR4 antaganist
(PCX). Biodistribution study indicated that the majority of injected polyplexes can
accumulated in injured renal rubule cells. Transfection effect of the polyplexes in
unilateral I/R injury mouse model showed a better silencing effect complared with
hydrodynamic injection, which providing a novel dual-functional pharmacological
method for treatment of AKI.
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Chapter 1. Introduction
1. Renal Anatomy and Selective Permeability
1.1. Renal Anatomy
Kidneys are organs that are highly vascularized and function as osmoregulators by
selective filtration, resorption, secretion and excretion. As shown in Scheme 1A, one
kidney of healthy adult human contains about one million nephrons which are the units
of kidney [1]. One nephron is composed of a renal corpuscle and a hairpin-shaped tubule.
Renal corpuscle consists of a cluster of capillaries named glomerulus and Bowman’s
capsule. Proximal tubule, loop of Henle, distal tubule and collecting duct make up to the
whole tubule system. The glomerulus prevents large molecules, blood cells and most
proteins from elimination while filtering fluid and waste products into tubules in which
several minerals are reabsorbed back to bloodstream and wastes are removed into urine.
1.2. Selective Permeability
The glomerular filtration barrier, located within the glomerulus of the nephron, is
made up of three different parts, including glomerular endothelial fenestrations [2],
glomerular basement membrane (GBM) [3], and podocytes [4] (Scheme 1B). The
glomerular endothelial fenestrations have the pore size of around 100 nm in diameter [5].
The GBM is a 300-nm-thick connective tissue membrane with presence of heparin sulfate
[6] and negatively charged proteoglycans. Its average pore size is 3 nm [7]. The GBM
serves as a size and charge-selective filtration barrier. The podocyte slit pores attached
over the surface of the GBM towards to the urinary space has average width of 15 nm [8].
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Taken together, the glomerular filtration barrier functions as an effective size cutoff for
the molecules or particles with size less than 10 nm to enter urinary space from the blood
circulation [9]. In other words, structural features of the glomerular barrier can be a
criterion for nanoparticles design to target kidney in diverse renal diseases.
The synthesis and application of nanoparticles have been attracted much attention in
biopharmaceutical areas, such as drug delivery [10, 11], therapeutics [12] and diagnostic
imaging [13, 14]. Effective therapeutic outcomes require specific features of nanoparticles
to overcome biological barriers, accumulate in target tissue and escape from rapid
clearance [15, 16]. Therefore, it is of great importance to understand the effect of different
properties of nanoparticles on biological distribution [17].
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Scheme 1. Renal anatomy. A) Nephron of kidney which consists of renal corpuscle and
hairpin-shaped tubules. B) Detailed structure of glomerulus (Adapted from [18]).
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1.2.1

Nanoparticle Size
The effect of nanoparticle size on in vivo biodistribution has been widely

investigated by several studies. Nanoparticles smaller than 10 nm can be subject to rapid
clearance by kidney and be excreted from the body. Over 50% of injected dose of
nanoparticles can be excreted via renal clearance 4 h after administration if hydrodynamic
diameter is below 5.5 nm [9, 15]. Larger nanoparticles over 100 nm are taken up and
degraded by spleen and liver [19]. Nanoparticles with size between these two ranges (10100 nm) typically have longer circulation time in blood and will not be filtered by kidney
into the urine unless they are degraded into smaller particles [20, 21]. Given that some
studies have shown inorganic nanoparticles with the size ranging from 12-16 nm passed
through this filtration threshold [22], this may not be a strict rule for renal clearance of all
types of nanoparticles and each study should be case-by-case due to distinct chemical
composition and size-distribution profile of each type of nanoparticles.
1.2.2

Nanoparticle Charge
The surface charge of nanoparticles plays an important role in determining

nonspecific cellular internalization and protein absorption during circulation which are
the concerns when it comes to systemic delivery. Among nanoparticles with positive,
negative and neutral charge, highly positively charged nanoparticles have the highest rate
of cell uptake. It has been also well accepted that nanoparticles with highly positive charge
are more subject to protein binding and uptake by phagocytes, leading to high nonspecific
internalization rate and rapid clearance by reticuloendothelial system (RES) [23, 24].
Compared to neutral nanoparticles, nanoparticles with negative charge still have more
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non-specific cellular uptake [25]. Yamamoto et.al. demonstrated negatively charged
micelles exhibited less uptake in liver and spleen than neutral micelles due to synergic
steric and electrostatic repulsion [26].
Given the negative charge of the GBM, charge selectivity is also an important
criterion of nanoparticles design for kidney filtration or targeting different renal cells.
Gold nanoparticles with positive charge accumulate in glomeruli 24 h after administration,
whereas neutral and negatively charged gold nanoparticles do not. Neutral gold
nanoparticles accumulate extensively in the arteries and negative gold nanoparticles are
distributed in the kidney homogeneously, indicating the influence of surface charge on
gold nanoparticles filtration by kidney [27].
1.2.3

Nanoparticle Shape
The structural features of nanoparticles are also responsible for dramatically different

renal clearance profile which is important aspect for design of targeted drug delivery
systems. Although it is well recognized that nanoparticles less than the 10-nm cutoff of
the kidney filtration barrier can pass through GBM, nanoparticles larger than 10 nm but
with high aspect ratios have been demonstrated to cross GBM paradoxically. Several
studies have demonstrated that single-walled carbon nanotubes with average diameter
less than 10 nm and average size 100 to 500 nm had rapid and effective renal clearance
with half-life of a few hours [28-31]. Based on the multimodal imaging methods, including
simultaneous dynamic positron emission tomography, near-infrared fluorescence
imaging and microscopy, Ruggiero and colleagues demonstrated that hydrostatic forces
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in glomerulus make the long axis of carbon nanotubes in a perpendicular orientation to
GBM, thereby their short axis is oriented horizontally to GBM [30]. Another group showed
the consistent result by transmission electron microscopy imaging [31].
2. Acute Kidney Injury
Acute kidney injury (AKI) can be characterized by an abrupt decline in the
glomerular filtration rate over a period of minutes to days that inhibits balance of
electrolyte, fluid and acid/base [32]. Clinically, AKI is mainly triggered by toxic responses
to medications, ischemia which results from a reduction of blood flow in kidney by
decreased cardiac output (cardiac surgery), and sepsis [33-35]. It is a complex disorder
and impacts about 13.3 million people annually [36]. There are about 1.7 million people
who die annually from AKI in the world [37-39]. The long-term outcomes of AKI for
patients may further develop into chronic kidney disease and end-stage renal disease,
which can lead to poor life quality and high long-term costs [40, 41]. Although people
have achieved substantial progress in treating AKI clinically by intensive care medicine
and dialysis, the prognosis has not significantly been improved and the mortality
remained 30-50% over the last decades [42]. Therefore, AKI is a major global health
problem that is associated with high morbidity and high mortality.

In the past, there has been no uniform accepted definition for AKI, which made it
difficult to clarify the incidence of AKI and hindered early recognition and management
of AKI. As lots of efforts of basic and clinical researchers have been focused on AKI over
the last decades, there is a great need to define a uniform criteria for AKI. The Kidney
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Disease: Improving Global Outcomes (KDIGO) group has recognized these limitations
and proposed a universal definition and staging system of AKI for practice, research and
public health [43], which describes that serum creatinine and urine output are the
standard diagnostic biomarkers for measuring kidney function. As is shown in Table 1,
AKI occurs within a broad spectrum ranging from the small changes in blood chemistry
of patients (mild injury) to renal failure that needs renal replacement therapy (most severe
impairment).
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Table 1. KDIGO staging system for AKI (Adapted from [43]).
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2.1 Pathophysiology of AKI
The mechanisms of AKI have been well studied by researchers in recent decades.
The understandings most derived from the work in animal models have provided
promising insight into the underlying pathophysiology [44, 45]. Based on animal models
of AKI that represent renal ischemia-reperfusion injury and nephrotoxicity, AKI is most
likely to be a complicated disease that can be induced by several potential pathways and
mechanisms of injury. Generally, the coagulation system is locally activated when the
kidney has energy failure or renal cells are exposed to toxic medications [35, 46].
Leucocytes infiltrate the kidney [47], inflammatory cytokines and chemokines are released
[48-50] and oxidative stress is activated [51]. The activation of coagulation, oxidative stress
and inflammatory infiltration will further lead to vascular endothelial cell damage and
microvascular congestion [52-54]. The sustained activation of these pathogenic factors will
again amplify the inflammatory cascades, leading to apoptotic cell death [55, 56]. Some
changes also occur on intracellular level such as loss of polarity [57] and adhesion to the
basement membrane tubular cells [58]. Moreover, AKI induces distant organ dysfunction
called organ cross-talk including liver, heart, lung and brain, emphasizing the complexity
of its biological response [59, 60].
2.1.1 Microvasculature Injury
The renal microvasculature plays a key role in determining vascular tone, leukocyte
function in the pathophysiology of AKI [61]. Kidney is an organ with a high energy
demand but a relatively low net oxygen extraction, which makes it susceptible to the
changes of renal oxygen during any vascular ischemia and perfusion [48]. In healthy state,
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adequate oxygen supply to the kidney is necessary for homeostatic control of renal
function by the production of mitochondrial adenosine triphosphate (ATP), nitric oxide
(NO) and reactive oxygen species (ROS) [62]. Once the kidney is injured, microvasculature
system is damaged and the balance between ATP, NO and ROS is broken, leading to a
series of subsequent pathogenic effects such as hypoxia and oxidative stress. The
endothelial cells are activated and express new cell surface markers due to damage of
microvascular endothelium and changes in the glycocalyx, which further promote the
recruitment and adhesion of leukocytes and platelets, change oxygen delivery and trigger
additional inflammation and endothelial cell injury [63, 64]. In addition, oxygen delivery
and supply can be influenced by increase in vascular permeability, and production of
vasoconstrictive prostaglandins and oxidative stress by injured tubule cells [63, 64]. The
reduction in vascular endothelial growth factor (VEGF) and increase in transforming
growth factor beta (TGF-β) signaling pathways would result in reduced density of
peritubular capillary that is responsible for the development of hypoxia and renal fibrosis
[65].
2.1.2 Inflammation
Immune response can be classified into two different types: innate immune system
and adaptive immune system, both of which are essential for the initiation of
pathophysiology of AKI. The innate immune system has cells that are already present in
the body and responsible for fighting microbes at the early response to injury. Such cells
include macrophages, neutrophils, dendritic cells (DCs), natural killer (NK) cells and
natural killer T cells. Besides, soluble molecules and membrane-associated receptors such
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as complement, cytokines and toll-like receptor (TLR) are also important contributors
to tubular injury. On the other hand, the adaptive immune system is initiated by specific
pathogens that are able to overcome innate immune defenses. It comprises DC maturation
and antigen presentation, T lymphocyte activation and proliferation, as well as T to B
lymphocyte interactions, which are normally silent.
It is well known that robust inflammation response is activated following renal
ischemia reperfusion [66]. Such activation triggered by the damage of tubule cells includes
not only innate immune response but also adaptive immune response. During reperfusion,
blood rich in innate immune components passes through injured kidney and accelerates
the renal damage. A number of pro-inflammatory cytokines and chemotactic cytokines,
such as TNF-α, IL-1β, IL-6, TGF-β and ENA-78 (epithelial neutrophil-activating protein
78), are synthesized and produced following renal ischemia reperfusion injury [66].
Cytokines have been proved to be responsible for both local and distant organ injury in
AKI. Renal injury is attenuated during ischemic acute renal injury by means of direct
blockade of certain cytokines [67, 68]. Additionally, leukocytes are recruited into the postischemic kidney, leading to increase in vascular permeability and destruction of epithelial
and endothelial cell integrity [69]. Meanwhile, the tubular injury also activates DCs and
thus activates naïve T cells to proliferate in an antigen-specific fashion, implicating the
initiation of adaptive immune response.
2.1.3 Reactive Oxygen Species
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Kidney is an organ that can not only directly produce a small amount of ROS in
the course of renal oxidative metabolism [70], but also is susceptible to the damage by
ROS [71-73]. Healthy kidney tolerates ROS without any obvious adverse effects only if
their concentration is maintained at a low level. However, excessive ROS produced by
renal cells themselves or infiltrating cells ( neutrophils and macrophages) in injured
kidney can contribute to, or even further exacerbate several types of renal cell damage [71,
74]. During ischemia, the reduction of molecular oxygen within cells leads to intracellular
and extracellular ATP depletion, producing increased ATP degradation products
including adenosine, hypoxanthine, xanthine and a shift towards anaerobic metabolism
[75]. However, on reperfusion, the initial increase in oxygen delivery amount exceeds the
amount needed for cellular metabolism from anaerobic pathways back to aerobic
pathways. The whole process would lead to generation of damaging free radicals and a
wide variety of ROS are generated, including superoxide radical, hydrogen peroxide and
hydroxyl radical.
ROS contribute to cellular signaling and further affect multiple aspects of cellular
functions such as proliferation, migration, gene expression and apoptosis [76]. Generally,
there are thought to be three main pathways for the generation of ROS during ischemiareperfusion injury: 1) conversion of xanthine dehydrogenase to xanthine oxidase, 2)
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation and 3)
uncoupling of the mitochondrial electron transport chain. Several studies have
demonstrated that treatment with antioxidants or free radical scavengers can diminish
acute renal injury. Noiri et al. showed the protection effect on rat kidney against ischemia
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by targeting inducible nitric oxide synthase with oligodeoxynucleotides [77]. Ma and
colleagues reduced cisplatin-induced AKI using saikosaponin-D which acts as a ROS
scavenger by inhibiting MAPK and NF-κB signaling pathways [78].
2.1.4 Apoptosis
Apoptosis, an energy-dependent and programmed cell death, is another major
etiological factor of AKI, which occurs in epithelial cells when they are undergoing a
severe renal injury. As shown in Scheme 2, the mechanisms of apoptosis are complex and
can be divided into two major pathways during ischemic renal tubule cell injury: intrinsic
and extrinsic pathways.
It is now widely accepted that mitochondria is a major site for apoptosis and plays
an important role in determining and regulating intrinsic and extrinsic pro- and antiapoptotic process [79, 80]. During ischemic renal injury, stress-induced increase of
mitochondrial permeability permits the production of free radicals [79], ATP depletion
[80] and release of pro-apoptotic proteins, cytochrome c, and in turn activates caspase-9
[81]. The mitochondrial permeability transition has been well recognized to be regulated
by apoptotic effectors, Bcl-2 family proteins [82]. Bax and Bak are the pro-apoptotic
members of Bcl-2 family proteins that increase mitochondrial membrane permeability and
promote apoptosis, whereas Bcl-2 and Bcl-XL are anti-apoptotic factors that maintain
mitochondrial integrity and thus suppress apoptosis. During renal ischemia-reperfusion
injury, the Bax/Bcl2 ratio, a decisive factor for programmed cell death [83], is increased
due to the activation of Bax [84, 85] and inactivation of Bcl2 [86, 87]. Inhibition of apoptosis
by blocking caspase or Bcl-2 proteins in ischemia animal models motivated the
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development of therapeutic treatments [88, 89]. Mei et al. made double knockout of Bax
and Bak in mice kidney proximal tubules and found ameliorated apoptosis in unilateral
urethral obstruction model. This finding indicated that Bax and Bak together play a key
role in mediating intrinsic apoptosis in AKI [90].
Extrinsic apoptosis pathway is induced by the binding of death receptors and death
ligands of the tumor necrosis factor (TNF) family on the cell surface. Death receptors
include Fas and tumor necrosis factor-alpha (TNF-α). Activation of such death receptors
leads to activation of downstream caspases to induce apoptosis, such as caspase 8 and
caspase 10 [91].
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Scheme 2. Major intrinsic and extrinsic signal pathways of apoptosis in renal cells exposed
to stress (Adapted from [56]).
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2.2 Diagnosis and Management of AKI
AKI clinical evaluation mostly includes two parts: history examination and
thorough physical examination. These two examinations are critical for determining and
categorizing AKI. The history examination should be divided into drug history and social
history examinations. Drug history should be considered for any uses of over-the-counter
formulations, herbal remedies, and recreational drugs. Any exposure to tropical disease
should be taken as social history. For physical examination, fluid status of patients should
be monitored, any signs of acute and chronic heart failure, as well as infections should be
examined, any skin rashes can also indicate systemic illness. Laboratory evaluation
should include parameters such as serum creatinine (Scr), blood urine nitrogen (BUN),
electrolytes, complete blood count and differential urine output.
Due to the complexity of AKI, all medications that underwent clinical trial failed
and there are no effective pharmacotherapies for treating AKI. So far the clinical
management of AKI is still primarily supportive. The key to management is to correct
hypovolemia and assure adequate renal perfusion through fluids resuscitation [92]. PBS
or human albumin fluid are preferred for fluid resuscitation over hydroxyethylstarch
because of its nephrotoxicity [93]. In addition, control of electrolyte imbalance is essential
for prevention or treatment of AKI. Insulin and calcium gluconate and sodium
polystyrene sulfonate (Kayexalate) are common methods that can be used to control
electrolyte

imbalances,

such

as hyperkalemia, hypermagnesemia,

hyponatremia,

hypernatremia and metabolic acidosis. Besides these treatments, some other auxiliary
therapies should be involved simultaneously with standard management practices.
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When AKI has potentially life-threatening complications, such as uncontrolled
symptomatic fluid overload, severe persistent metabolic disturbances and refractory
hyperkalemia, renal replacement therapy is required [94, 95]. However, the timing of
initiating renal replacement therapy is still debatable [96, 97] and the cost of dialysis is a
major burden for patients and healthcare systems. Based on recent advances in renal
injury and repair signaling pathways, several pharmacological agents including
antioxidants, anti-apoptosis or anti-inflammatory agents, growth factors and vasodilators
for improving renal functions have developed [98]. However, so far no pharmaceutical
agents are successful in clinical trials [99-101].
3. Animal Models of AKI
To better understand pathophysiological mechanisms or study pharmacological
therapies of AKI, in vivo animal models are indispensable to mimic situation in human
body [102]. There are various animal models of AKI have been developed and tested. The
most commonly used animal models for AKI are renal ischemia-reperfusion (IR) model
and nephrotoxicity model which is induced by drugs like cisplatin. The IR model can be
divided into unilateral and bilateral renal IR model on the basis of the site of injury [103105]. The unilateral renal IR model can further be categorized as two subtypes: unilateral
IR with contralateral nephrectomy [105, 106] or without contralateral nephrectomy [107,
108]. Compared to unilateral IR model, the bilateral IR model is more common because it
is better to mimic the condition of human pathology [109, 110]. However, compared with
nephrotoxicity model, these models might have big variations leading to inconsistency in
results.
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4. Kidney-targeted Drug Delivery Systems
Nanoparticles have attracted increasing attention over the past few decades due to
their effective diagnostic and therapeutic functions in several diseases, such as cancer.
Nanoparticles can be engineered to improve delivery efficacy to focus by overcoming
several barriers that are associated with systemic drug administration, thus minimize
non-specific accumulation and side effect in other organs. Lots of carrier systems have
been developed and employed to optimize nanoparticles for prolonged circulation time
in blood, targeting to specific organs or cell types. [111-113]. For example, Yang and
colleagues developed chitosan/siRNA nanoparticles that are not only taken up specifically
by renal proximal tubule epithelial cells through megalin-mediated pathway, but also
enable gene silencing in those cells [114]. Kooijmans et al. coated extracellular vesicles
with nanobody-PEG-micelles, by which they improved poor cell specificity and increased
circulation time in vivo [115].
Given the lack of pharmacological therapies for AKI, the kidney-targeted drug and
siRNA delivery has drawn much attention in recent decades in order to improve the
delivery efficacy in kidney. Although numerous carrier systems have been commonly
used and shown promising effect in several diseases, only a few carrier systems like
prodrugs and macromolecular carriers are the most frequently used strategies to achieve
the goal of kidney-targeted drug delivery due to the size restriction of glomerulus
filtration barrier. Drug targeting to the proximal tubule cells, which are the primary
injured site in AKI could provide better treatment by means of enhancing the therapeutic
efficacy of drugs and lowering unwanted side effects in other organs. In general, it only
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allows carrier systems with a hydrodynamic diameter less than 10 nm to reach the site
[9]. However, some studies also showed contradictory results that inorganic nanoparticles
with the size ranging from 12-16 nm [22] and single-walled carbon nanotubes with
average diameter less than 10 nm and average size 100 to 500 nm [28-31] can pass through
the filtration threshold.
4.1 Polymeric Carrier Systems
Several studies have demonstrated that polymeric carriers had a potential to target
kidney and might be good candidates for drug and siRNA delivery. The copolymers of
N-vinylpyrrolidone with anionic maleic acid showed increased renal accumulation when
compared with the unmodified polyvinylpyrrolidone (PVP) [116]. Another polymeric
carrier that has widely been used for drug and siRNA targeting to kidney is low molecular
weight chitosan (LMWC). 50% N-acetylated LMWC demonstrated the capability to
specific target kidney [117, 118]. Afterwards, the LMWC-based carriers have been further
explored and showed the potential for delivering drug and siRNA to kidney.
Glucosamine, the fundamental unit of LMWC, showed enhanced protective effect against
renal ischemia-reperfusion injury after conjugated to triptolide [119]. Chitosan/siRNA
nanoparticles also demonstrated therapeutic effect against unilateral ureteral obstruction
induced kidney injury [120].
4.1.1 Protein- and Peptide-based Carrier Systems
Low molecular weight proteins (LMWPs) and peptides were also extensively
studied for renal delivery of therapeutic drugs. Lysozyme has a molecular weight of 14
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kDa and can be freely filtered in the urine with a glomerular sieving coefficient of 0.8
[121], followed by the reabsorption by the proximal tubule cells. Therefore, lysozyme is
one of the most popular protein carriers and has been conjugated to various drugs for
specific renal delivery. For example, Prakash et al. has coupled Y27632 to lysozyme and
they found that Y27632-lysozyme specifically accumulated in the kidney. The ischemiareperfusion induced tubular damage was significantly inhibited after treatment of
Y27632-lysozyme, which was indicated by decreased level of inflammation and fibrosis
[122]. Although LMWPs showed promising ability as carrier systems for renal targeting,
some defectiveness like cardiovascular toxicity and complexity in modification may
hinder their applications.
Besides LMWPs, peptides are still widely studied in renal targeting drug delivery.
Wischnjow et al. conjugated ciprofloxacin to the peptide-based drug carrier, (KKEEE)3K,
and successfully demonstrated the high selectivity to renal proximal tubule cells,
indicating the excellent renal targeting potential of the peptide carrier [123]. Janzer and
colleagues found that the targeting specificity of (KKEEE)3K did not change after drug
conjugation even with a multiple-drug loading of a model drug, α-lipoic acid. While other
peptide molecules, such as (KKQQQ)3K, showed a total loss of kidney specificity. This
finding demonstrated (KKEEE)3K as a promising carrier candidate for treatment of AKI
[124].
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4.1.2 Prodrugs
Prodrugs are compounds that can only be activated in the body after cleavage of
chemical bonds [125-127]. Small drug molecules usually have poor chemical or metabolic
stability, low water solubility and obvious toxicity in non-specific organs. Hence,
development of prodrugs can improve these disadvantages and further give rise to patent
line extension.
4.1.2.1 Folate Modified Prodrugs
Although the expression of folate receptors is well recognized in tumor cells [128,
129], the folate receptors are expressed in the kidneys as well. Folate can be filtered by
glomerulus

and

reabsorbed

by

renal

tubule

cells

as

the

form

of

5-

methylenetetrahydrofolate. Mathias and colleagues conjugated folic acid to diethylene
triamine pentaacetic acid (DTPA) by an ethylenediamine spacer forming DTPA-folate
conjugate [130]. They found the accumulation of the radiolabeled DTPA-folate in both
kidneys was approximately 23 % of the injected dose per gram tissue 4 h post intravenous
injection. There was about 90% of DTPA-folate conjugates reduced in the kidneys after
pretreatment of folic acid, which indicating that folate receptors in kidneys played an
important role in the renal uptake of DTPA-folate conjugates. The other similar
biodistribution study of [99mTc](CO)3-DTPA-folate demonstrated a higher renal
accumulation which is about 50% of injected dose per gram tissue 4 h post intravenous
injection [131]. However, the application of folate targeting in kidneys has been limited
since folate receptors are not only expressed by kidneys [132].

22
4.1.2.2 Amino Acid Modified Prodrugs
Some endogenous enzymes have relatively high concentration in kidneys and hence
their substrates, such as L-decarboxylation and γ-glutamyltranspeptidase, can be utilized
to conjugate small drugs for targeting proximal tubule cells. Wilk and co-workers
conjugate γ-glutamyl with dihydroxyphenylalanine to give γ-glutamyl-dopamine
(GGDA) [133]. Its biodistribution study indicated that, compared with the administration
of an equivalent dose of dopamine, an increased accumulation of dopamine in the kidney
was observed following GGDA oral administration to mice. Even though dopamine has
been proved to have no therapeutic effect on renal disease in clinic [134], this type of drug
carrier can be conjugated with other drugs for renal targeting.
4.1.3 Nanoparticles
Besides above carrier systems, nanoparticles have a great potential as carriers for
drug and siRNA delivery to kidney. Choi et al. demonstrated that nanoparticles with
average hydrodynamic diameter of 75±25 nm have ability to target kidney mesangium by
comparing renal distribution of polyethylene glycol (PEGylated) gold nanoparticles with
different sizes [135]. Based on these findings, they first established the criteria of
nanoparticles construction for targeting diseases associated with mesangium. Alidori and
co-workers successfully delivered Trp53- and Mep1b-targeted siRNA to proximal tubule
cells simultaneously using an ammonium-functionalized single-walled carbon nanotubes
(fCNT) and mice lived longer with mitigated AKI [136]. In evaluation of pharmacokinetic
profile of fCNT/siRNA nanoparticles in primates, it showed comparable to mice which
would be a promising approach for clinical application. Another new finding broads the
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effective treatment of AKI. Hu et al. designed dexamethasone-loaded E-selectintargeting sialic acid-PEG-dexamethasone conjugate micelles and this nanoparticles
showed enhanced kidney accumulation due to specific interaction between sialic acid and
E-selectin , resulting in anti-inflammatory efficacy for acute kidney injury [137].
5. RNA Interference Therapy
RNA interference (RNAi) is a powerful gene silencing process which is guided by
small RNAs including small interfering RNAs (siRNAs) and microRNAs (miRNAs) [138].
These small RNAs down regulate key gene expressions through sequence-specific
degradation of mRNAs or inhibition of protein translation, by which the cell fate is
determined [139-141]. In addition, the endogenous gene expression can also be
suppressed by RNAi therapy [142, 143].
5.1 Small Interfering RNA
Small interfering RNAs (siRNA) consist of 20-25 base pairs and downregulate the
expression of sequence-specific gene by post-transcriptional gene silencing pathway [144,
145]. Mechanistically, after entering cytoplasm siRNAs bind multiprotein RNA-inducing
silencing complex (RISC) and then sequence-specifically target mRNA. The argonaute-2
which is also called slicer further triggers the cleavage of mRNA, leading to gene silencing.
Unlike other gene technologies, siRNAs have several unique advantages, such as high
degree of specificity to mRNAs, non-immunogenic property and high resistance to
ribonucleases. With the development of technology for high-throughput gene expression
and more understanding in several diseases, siRNAs have received increasing attention
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and become one of the most promising therapeutic method for gene therapy [146, 147].
Soutschek and co-workers overcame the obstacle of in vivo gene silencing by intravenous
administrating

siRNAs

which

are

chemically

stabilized

by

modification

of

phosphorothioate backbone and 2’-O-methyl sugar on both sense and antisense strands
[148]. They demonstrated decreased mRNA level of apolipoprotein B (apoB) in liver and
jejunum, reduced plasma levels of apoB protein, as well as reduced total cholesterol.
Moreover, they silenced human apoB in a transgenic mouse model, which indicates the
promising potential for siRNAs in the treatment of human diseases.
5.2 Carrier Systems for siRNAs Delivery
The employment of naked siRNA is always associated with several inherent
problems due to the poor cellular permeability, easy degradation by endogenous enzymes
and off-target effects [149]. To further increase the delivery efficiency of siRNAs to the
targeted tissues in vivo, a wide variety of carrier systems have been developed [150, 151].
Carrier systems can be divided into two categories: viral carriers and non-viral carriers.
The viral carriers have some advantages including high transfection effect and long-term
gene expression while disadvantages such as high toxicity, immunogenicity and
economic issue hinder the application.
Non-viral carrier systems such as cationic lipids and cationic polymers have drawn
much attention in improvement of gene therapies. These cationic delivery systems form
polyelectrolyte complexes with the oppositely charged siRNA. In general, cationic lipids
are made up with inner aqueous compartment which contains siRNAs and outer
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phospholipid bilayer. Cationic polymers, like chitosan, polyamidoamine, polypeptides
are chemically synthesized and form complexes with siRNAs. Reddy et al. encapsulated
paclitaxel and siRNA targeting Bcl-2 into a nanocarrier system which consists of kojic acid
backbone-based cationic amphiphile [152]. By doing so, they successfully inhibited cell
proliferation and thus reduced tumor growth, demonstrating an efficient method for
systemic delivery of siRNA. For another example, Dahlman et al. synthesized epoxidemodified lipid-polymer hybrids (7C1) for siRNA delivery to endothelium with high
efficiency [153]. This formulation specifically reduced endothelial gene expression in lung
to only 10% at a dose of 0.10 mg/kg and to 50% when the doses are as low as 0.02 mg/kg
with no obvious gene expression decrease in other cells including luminary immune cells,
hepatocytes and peritoneal immune cells. 7C1 nanoformulations should be a new
candidate for siRNA delivery to endothelium in the future.
6. Chemokines and Chemokine Receptors
Chemokines, also known as chemotactic cytokines, are small heparin-binding
signaling proteins secreted by various stromal and epithelial cells and able to direct the
movement of circulating leukocytes to inflammatory or injured sites via interacting with
their respective chemokine receptors [154]. Chemokines and their receptors are well
recognized as contributors for the pathogenesis of several diseases. And blockade of
chemokine receptors has been used to regulate inflammation in many diseases. There are
approximately 50 human chemokines which can be divided into four groups based on the
number and spacing of N-terminal cysteines (Table 2) [155-157]. Among chemokines, CC
chemokines are the largest family and have four cysteine residues with first two adjacent
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to each other. CXC chemokines are the chemokines that have a single amino acid
residue within the first two canonical cysteines. Fractalkine [158, 159] and lymphotactin
[160] is the only member of the other two families, CX3C and XC respectively. There are
19 different chemokine receptors that all belong to the seven-transmembrane G-proteincoupled receptor family. Chemokines bind to their correspondent chemokine receptors
on cell surface, by which signaling cascades are activated leading to cell rearrangement,
change of shape or cell movement of action.
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Table 2. CC, CXC, CX3C and XC Families of Chemokines and Chemokine Receptors
(Adapted from [161]. Reproduced with permission from scientific reference citation,
Copyright Massachusetts Medical Society).
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Continued Table 2. CC, CXC, CX3C and XC Families of Chemokines and Chemokine
Receptors (Adapted from [161]. Reproduced with permission from scientific reference
citation, Copyright Massachusetts Medical Society).
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6.1 CXCR4 and its Ligand SDF-1
C-X-C chemokine receptor 4 (CXCR4) is one of the most commonly expressed
chemokine receptors in many tissues, which plays a vital role in the process of metastasis
in multiple types of cancers and inflammatory diseases [162-165]. Binding with its ligand,
stromal cell-derived factor-1 (SDF-1), divergent intracellular signaling transduction
pathways are initiated, which can result in a variety of responses such as chemotaxis,
cancer cell proliferation, recirculation and hematopoiesis of leukocytes [166, 167]. Driven
by CXCR4 expressed in the primary tumor cells and leukocytes, the cells metastasize to
secondary sites where SDF-1 is highly expressed, such as lung, liver, bone marrow, and
brain [168]. For example, phosphatidylinositol-3-kinase (PI3K) pathway is activated by
CXCR4/SDF-1 axis, leading to activation of protein kinase AKT, which is the key mediator
in cancer cell migration and survival [169]. Moreover, the secretion of matrix
metalloproteinases (MMPs) is increased and then extracellular matrix further degrades
after CXCR4 activation, which facilitates the invasion process. Mitogen-activated protein
kinase (MAPK) pathways is stimulated by CXCR4/SDF-1 axis as well, resulting in increase
in cancer cell proliferation and survival [170]. Blocking the CXCR4/SDF-1 interaction by
antagonizing CXCR4 can inhibit macrophage infiltration, induce tumor growth arrest and
prevent metastatic spread [171, 172].
6.2 The Role of CXCR4 in AKI
Inflammation is a significant pathophysiological component of AKI [164, 173].
Cytokines and chemokines are involved in response to nephrotoxicity or reperfusion
injury, leading to a proinflammatory microenvironment. CXCR4 and its ligand SDF-1 are
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believed to be involved in recirculation and hematopoiesis of normal leukocytes,
including neutrophils, monocytes and lymphocytes [167, 172, 174], which are key
mediators of renal injury. Sustained high CXCR4 expression (on tubules or immune cells,
such as macrophages), in turn, exacerbates renal injury and promotes necrosis. Inhibiting
CXCR4 has been demonstrated to modulate immune system, leading to improved
therapeutic activity of AKI [173, 175]. Zuk and co-workers showed renoprotective role of
plerixafor (AMD3100) which is a small-molecule CXCR4 antagonist in renal ischemiareperfusion animal model [173]. After antagonizing CXCR4, plerixafor ameliorates AKI
by modulating leukocyte infiltration and reducing expression of proinflammatory
chemokines and cytokines.
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Chapter 2. Determinants of synthetic polymeric carrier systems for renal-targeting
in acute kidney injury
1. Introductions
Drug targeting to the proximal tubule cells, which are the primary injured site in
AKI could provide better treatment by means of enhancing the therapeutic efficacy of
drugs and lowering unwanted side effects in other organs. Synthetic polymers are often
used as carriers to target proximal tubular cells by means of either physically encapsulate
or covalently conjugate drugs [176-178]. In recent years, several studies have been
demonstrated that polymers have potential to target proximal tubular cells and might be
good candidate for drug carriers. Kamada et al. demonstrated that polyvinylpyrrolidoneco-dimethyl maleic anhydride [poly(VP-co-DMMAn)] had much higher accumulation
and longer retention time in kidneys than native polyvinylpyrrolidone (PVP). The
poly(VP-co-DMMAn)-modified superoxide dismutase also accelerated recovery from
mercuric chloride-induced acute renal failure [179]. Mitra et al studied the biodistribution
of N-(2-Hydroxypropyl) Methacrylamide (HPMA) copolymers with different molecular
weight and charge [180]. They synthesized neutral and negatively charged HPMA
copolymers with average molecular weights of 7 kDa, 21 kDa and 70 kDa. The negatively
charged 21 kDa HPMA copolymers showed highest renal accumulation 24 h after
intravenous injection in mice. These findings proved that the type and content of anionic
groups introduced to the polymers, as well as polymer molecular weight play a vital role
for renal cells targeting. However, the reported studies were performed in healthy
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kidneys and very little is currently known about how physicochemical properties of
polymers affect renal deposition in AKI.
Therefore, we synthesized and evaluated a library of polymers with a range of
molecular weights and different net charges. We compared the cellular uptake and
intracellular trafficking of polymers in mouse proximal tubular epithelial (MCT) cells at
both normoxia and hypoxia conditions. Additionally, by testing biodistributions of each
polymers in vivo, we explored and identified preferred polymer characteristics that
preferentially accumulate in proximal tubular cells in AKI animal model.
2. Materials and Methods
2.1 Materials
N-(3-Aminopropyl)

methacrylamide

hydrochloride

(APMA)

and

N-(2-

hydroxypropyl) methacrylamide (HPMA) were purchased from Polysciences, Inc.
(Warrington, PA). Methacrylic acid (MAA) was obtained from Acros Organics (Belgium,
NJ). 4, 4’-Azobis(4-cyanovaleric acid) (ACVA), 4-cyano-4-(phenyl carbonothioylthio)
pentanoic acid (CPAD) which was as a typical CTA and fluorescein O-methacrylate (FMA)
were from Sigma-Aldrich (St. Louis, MO). Cyclam (1,4,8,11-tetraazacyclotetradecane) was
purchased from Alfa Aesar (Ward Hill, MA). N,N’-hexamethylenebisacrylamide (HMBA)
was from Polysciences, Inc. (Warrington, PA). AMD3100 (base form) was from
Biochempartner (Shanghai, China). RPMI medium 1640, Dulbecco’s phosphate buffered
saline (PBS), and fetal bovine serum (FBS) were from Thermo Scientific (Waltham, MA).
Mouse renal tubular epithelial cells (MCT) was a kind gift from Dr. Padanilam (University
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of Nebraska Medical Center) and cultured in RPMI supplemented with 10% FBS. All
other reagents were from Fisher Scientific and used as received unless otherwise noted.
2.2 Methods
2.2.1 Synthesis of Polymers
The polymerization was achieved at 70 °C, employing ACVA as the initiator and
CPAD as the chain transfer agent. A typical protocol is as follows: APMA (178 mg, 1 mmol)
was dissolved in doubly distilled water followed by the addition of CPAD (6.24 mg, 0.02
mmol, target DPn = 45), ACVA (2 mg, 0.007 mmol) and FMA (7.15 mg, 0.018 mmol) in 1,4dioxane stock solution. The solution was added into a small glass vial and purged with
nitrogen for at least 30 minutes. The vial was placed in an oil bath for polymerization at
70 °C for 30 min, 3 h, and 4.5 h. After the polymerization, the solvent was dialyzed against
water for 3 days before final freeze-drying.
The polymerization of pMAA and pHPMA was conducted employing similar
procedure described above. The feed ratio, reagent and reaction time was according to
Table 2.
2.2.2 Polymer Characterizations
The

molecular

weights

of

pAPMA

were

analyzed

by

gel

permeation

chromatography (GPC) operated in 0.1 M sodium acetate buffer (pH 5.0) using Agilent
1260 Infinity LC system equipped with a miniDAWN TREOS multi-angle light scattering
(MALS) detector and a Optilab T-rEX refractive index detector (Wyatt Technology, Santa
Barbara, CA). The column used was TSKgel G5000PWXL-CP (Tosoh Bioscience LLC, King
of Prussia, PA) at a flow rate of 0.5 mL/min. Results were analyzed using Astra 6.1
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software from Wyatt Technology. The degree of polymerization was calculated from
the GPC.
The characterization of pMAA was conducted employing the same method but
using AquaGel PAA-202 (London, ON, Canada) column. The characterization of pHPMA
was conducted employing the same method but using 0.3 M sodium acetate buffer (pH
5.0).
The amount of conjugated FMA was determined on a SpectraMax iD3 Multi-Mode
Microplate Reader (Molecular Devices, CA). An amount of 1 mg of each dried polymers
was dissolved in 1 ml PBS and the fluorescence intensity of the solution was measured at
an excitation wavelength of 490 nm and an emission wavelength of 525 nm, which
corresponds to a peak maximum for FMA. FMA content was determined by comparison
to a FMA standard curve.
2.2.3 Cellular Uptake and Intracellular Trafficking of Polymers
Flow cytometry analysis was conducted to study the cellular uptake of polymers.
MCT cells (3 × 104) were seeded in 12-well plates and cultured to approximately 50%
confluence. The cells were incubated in 37 °C at a virtual pAPMA concentration of 2
µg/mL, pMAA concentration of 300 µg/mL or pHPMA concentration of 1 mg/mL for 24 h
in either normoxic or hypoxic (2% O2) incubator. The cells were then washed with PBS
twice, trypsinized and subjected to analysis using a BD FACS Calibur flow cytometer (BD
Bioscience, Bedford, MA). The results were processed using FlowJo software.
Intracellular trafficking was observed by LSM 800 Laser Scanning Microscope (Zeiss,
Jena, Germany). MCT cells were cultured on 24-well plates with round coverslip glass at
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5 × 104 cells/well. After 24 h, the medium was exchanged with fresh medium and a
solution of the studied polymers was added (same concentrations as cellular uptake).
After incubation for another 24 h in either normoxia or hypoxia incubator, the cells were
washed twice with PBS and fixed with 4% paraformaldehyde for 10 min and nuclei were
stained with Hoechst 33258 for another 10 min.
2.2.4 In vitro Cytotoxicity of the Polymers
Toxicity of the polymers was evaluated by Cell Titer Blue assay in MCT cells. The
cells (5 X 103 cells/well) were plated in 96-well microplates. After 24 h, the cultured cells
were treated with fresh medium and different polymers respectively. After further 24 h
of incubation at either normoxic or hypoxic condition, the medium was removed and
replaced with a mixture of 100 µL of serum-free media and 20 µL of CellTiter-Blue reagent
(CellTiter-Blue Cell Viability Assay, Promega). After 2 h of incubation, the fluorescence
(560/590 nm) was measured on a SpectraMax iD3 Multi-Mode Microplate Reader
(Molecular

Devices,

CA).

The

relative

cell

viability

(%)

was

calculated

as

[fluorescence]sample/[fluorescence]untreated X 100.
2.2.5 Induction of Ischemia-reperfusion Kidney Injury
To induce AKI, we used the animal model of unilateral or bilateral renal ischemiareperfusion (I/R) injury. All animal experiments followed a protocol approved by the
UNMC Institutional Animal Care and Use Committee. C57BL/6J male mice (8-10 week
old) were purchased from Charles River. All animals were given free access to food and
water. The non-fluorescent food was given at least 1 week before surgery. The mice were
anesthetized by intraperitoneal administration of ketamine (200 mg/kg) and xylazine (16
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mg/kg). For unilateral I/R injury, following left dorsal flank incision, renal pedicles were
bluntly dissected and a microvascular clamp (Roboz Surgical Instrument, Gaithersburg,
MD) was placed on the left renal pedicle for 30 min to induce unilateral I/R injury. During
the procedure, mice were kept well hydrated with warm saline and on 37 °C heating pad.
After 30 min of occlusion, the clamps were removed and kidney reperfusion was verified
visually. Then wound clips were used to close skin. Sham-operated right side underwent
the same surgical procedure, except for the occlusion of the renal arteries. The mice were
monitored until they woke up. Similar procedure was conducted to induce bilateral I/R
injury by placing microvascular clamp on both renal pedicle for 30 min. Sham-operated
control animals also underwent the same surgical procedure, except for the occlusion of
the renal arteries.
2.2.6 In vivo Biodistribution of Polymers
Biodistribution of the polymers in I/R mice was analyzed by ex vivo fluorescence
imaging. Each different polymers were administered via tail vein injection 24 h postsurgery. At 4 h and 24 h after administration, mice were killed and major organs were
isolated and imaged using Xenogen IVIS 200. Emission wavelength of 540 nm and
excitation wavelength of 500 was used to image organs. The fluorescence intensities from
liver and kidney was quantified using Living Image® 4.5 software. The radiant efficiency
of the kidney and liver was measured as (photons/sec/cm2/sr)/(µW/cm2). Background
fluorescence was subtracted prior to analysis. To study intracellular localization of
different polymers in kidney, bisected kidneys were embedded in OCT compound and
cut into 10 µm frozen sections. The frozen sections were either stained with DAPI, or
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stained with haematoxylin and eosin (H&E). Polymer localizations were visualized by
LSM 800 Laser Scanning Confocal Microscope (Zeiss, Jena, Germany). Histopathological
change was confirmed by H&E sections under EVOS microscope.
2.2.7 Tissue Homogenization
To quantify the amounts of polymers in I/R kidneys and sham-operated kidneys,
kidneys dissected from C57BL/6J mice bodies were finely minced with scissors and placed
in a homogenizer vessel. 750 µL RIPA buffer and HaltTM protease & phosphatase inhibitor
cocktail were added and tissues were subsequently homogenized. Homogenized samples
were centrifuged at 15,000 rpm for 15 min at 4 °C. The supernatant was used to quantify
polymer amount in kidneys by standard addition method using a fluorescence Symergy
2 Microplate Reader (BioTek, VT).
2.2.8 Statistical Analysis
Data are presented as the means ± SD. The statistical significance of the mean values
of all groups was determined by using one-way ANOVA. An unpaired t test was used to
compare the means of two different groups. A P value < 0.05 was considered statistically
significant.
3. Results and Discussions
3.1 Polymer Synthesis and Characterization
Polymers such as HPMA, APMA or MAA have been used as carriers of drugs and
siRNA to enhance their stability in vivo and as targeted delivery systems. Lots of lowmolecular weight therapeutic agents show improved activity when conjugated to or
encapsulated into carrier systems containing such polymers [181-183]. Because the
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biodistribution of such therapeutic agents is influenced by the properties of the carrier
system, we developed a library of 9 fluorescently labeled polymers, including neutral
pHPMA, negatively charged pMAA, and positively charged pAPMA, with reversible
addition-fragmentation chain-transfer (RAFT) polymerization method to evaluate
properties both in vitro and in vivo. Table 3 shows the RAFT polymerization condition of
pAPMA, pMAA and pHPMA, in which polymers are prepared by copolymerization of
the corresponding monomers with a fluorescein-containing co-monomer using CTA
transfer agent and ACVA initiator at 70°C. The feed ratio of monomer/CTA/ACVA/FMA
is variable according to different monomers. All polymers are characterized by GPC. The
molecular weight range is from 5 kDa to 36 kDa with a low Mw/Mn value (Table 3). The
fluorescence of the synthesized polymers is used to track the subcellular fate and
distribution of the polymers both in vitro and in vivo. The content of FMA is quantified for
each polymers (Table 3) in order to enable the comparison of fluorescence data obtained
from the different polymers. The GPC curves for all polymers are shown in Figure 1.
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Table 3. Polymer Characterizations
a. Initial molar ratio of monomer/CTA/ACVA/FMA

pAPMA-6
pAPMA-16
pAPMA-30

1.5
1.0
0.5
0.0
17

18

19

20

21

Retention time (min)

22

B
pMAA-5
pMAA-16
pMAA-31

1.5
1.0
0.5
0.0
10

Figure 1. GPC curves of all polymers.

12

14

16

Retention time (min)

18

Normalized refractive index signal

A

Normalized refractive index signal

Normalized refractive index signal
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C
pHPMA-5
pHPMA-16
pHPMA-36

1.5
1.0
0.5
0.0

20

25

30

Retention time (min)
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3.2 Cellular Uptake and Intracellular Trafficking of Polymers
For many applications of RAFT generated polymers in biopharmaceutical use,
potential for toxicity is a concern. Therefore, it is important to understand toxicity of
polymers in MCT cells, mouse renal proximal tubule cells, before conducting cellular
uptake. To evaluate cytotoxicity of polymers, CellTiter Blue assay was conducted in MCT
cells (Table 4). Because we used unilateral renal ischemia-reperfusion injury model
(explained below) to study biodistribution of polymers in vivo, we evaluated cytotoxicity
at both normoxia and hypoxia conditions. We found there was no obvious toxicity after
we incubated MCT cells with pHPMA at 1 mg/mL at both normoxia and hypoxia
regardless of size. The HPMA based copolymers have been extensively examined as
biocompatible, non-immunogenic and non-toxic drug carriers [184, 185]. For pMAA and
pAPMA, generally the smaller was the size, the less toxic was the polymers. And IC50 at
hypoxia was generally lower than normoxia, which may result from more cellular uptake
of polymers at hypoxia. pAPMA showed much higher toxicity to MCT cells due to highly
positive charges.
In order to compare uptake of polymers in vitro at normoxia and hypoxia, we
investigated the cellular uptake of different polymers. MCT cells were selected and
incubated with the polymers for 24 h and cellular uptake was determined by flow
cytometry. The mean fluorescence intensity (MFI) ratio between normoxia and hypoxia
was showed in Figure 2. For pAPMA, cells had similar MFI after incubated at either
normoxia or hypoxia. Among pMAA, the fold of MFI for pMAA-5 was ~ 2.8, while
pMAA-16 and pMAA-31 didn’t show much diverse cell uptake at normoxia and hypoxia.
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For pHPMA with all three sizes, more polymers were taken up by MCT cells at hypoxia
and the highest ratio was observed with pHPMA-36, which was about 4 folds.
Flow cytometry yields semi-quantitative results for fluorescence taken up by cells
or attached to their outer membrane, therefore we used confocal laser scanning
microscopy to verify intracellular trafficking of each polymers. Similarly, the cells were
incubated with different polymers for 24 h and then imaged by confocal microscopy
(Figure 3). All polymers were clearly observed inside the cells. They were internalized
into the cells and mainly localized in the cytoplasm. Compared with normoxia, there was
no difference observed for cellular trafficking of pAPMA at hypoxia. For pMAA, a slightly
higher intensity was only observed for pMAA-5 after hypoxic incubation. However, the
fluorescence intensities in cytoplasm of pHPMA with all sizes were significantly increased
after cells were incubated at hypoxia. And the most significant difference was also
observed with pHPMA-36. These results of cellular uptake and intracellular trafficking
indicated that MCT cells had increased cell uptake at hypoxia for certain polymers, such
as smallest sized pMAA (pMAA-5) and those three pHPMA polymers at hypoxia, which
prompted us to further investigate the distribution in vivo.
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Table 4. IC50 of different polymers in MCT cells at normoxia or hypoxia condition. Cell
viability was measured by CellTiter blue after 24 h incubation at 37 °C.
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Figure 2. Cellular uptake of different polymers in MCT cells. Quantification of cellular
uptake is shown by mean fluorescence intensity (MFI) ratio between cells incubated at
hypoxia and at normoxia after 24 h. Data were shown as the mean ± SD (n = 3).
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Figure 3. Intracellular trafficking of different polymers in MCT cells by confocal
microscopy after 24 h incubation (63X).
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3.3 Renal accumulation of polymers in unilateral I/R mice
Polymer size and charge play an important role in kidney deposition because
glomerulus basement membrane filters small molecules by size and charge. Generally, in
healthy state, molecules with hydrodynamic diameter less than 5-7 nm or molecular
weight less than 68 kDa can pass this barrier. However, the barrier can be broken by
podocyte effacement in disease and large or charged molecules could accumulate in the
Bowman space due to the leaky and abnormal fenestrae after renal ischemia [186-188].
Therefore, we hypothesized that renal targeting of polymers can be impacted by AKI and
this impact can be associated with size or charge of polymers.
To understand how AKI affects the biodistribution, especially for renal
accumulation, of polymers with different sizes and charges, we established a well-known
kidney injury model, unilateral ischemia-reperfusion (I/R) model, where left renal artery
was clamped and renal injury was induced in the left kidney while the right kidney was
also exposed and remained intact. Mice were sacrificed at two designated time points, 4
h or 24 h post intravenously administration and major organs were isolated for ex vivo
fluorescence imaging (Figure 4A). Generally, we didn’t find any less polymers entering
into I/R kidneys due to reduced blood perfusion as compared to sham-operated kidneys
at these two time points. In contrast, we found polymers with certain size and charge
showed relative more accumulation in I/R kidneys at 24 h. Among negatively charged
pMAA and neutral pHPMA, pMAA-5 and pHPMA-36 showed most distinct
accumulation in I/R and sham-operated kidneys at 24 h. Region of interest (ROI) ratio
between I/R and sham-operated kidneys of these two polymers at 24 h was ~ 4, and the
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renal accumulation was similar at 4 h (Figure 4B). The higher the molecular weight of
pMAA (pMAA-16 and pMAA-31) or the lower the molecular weight of pHPMA
(pHPMA-5 and pHPMA-16), the less the fluorescence difference between I/R and shamoperated kidneys at 24 h. Sluggish and occasionally retrograde blood flow after I/R injury
and delayed clearance of macromolecules from the injured kidneys may lead to the
delayed and increased accumulation at 24 h [189, 190]. Pathological change of kidneys
after I/R injury, e.g. endothelial dysfunction, can also contribute to change in interaction
between macromolecules and kidneys at cellular level [189, 191]. These polymers did not
appear to be taken up to a significant extent by any organ other than kidneys, especially
for the two major organs of reticuloendothelial system, liver and spleen (Figure 4A & 6C).
In contrast, for positively charged polymers pAPMA, we didn’t observe any obvious
difference between I/R and sham-operated kidneys, except for high liver accumulation of
pAPMA-16 at 4 h and pAPMA-30 at 24 h. Positively charged macromolecules are usually
susceptible to rapid renal elimination and high non-specific uptake in liver [23, 24]. These
results indicated that AKI has size-, and charge-dependent effect on renal uptake of
synthetic polymers. Its potential to take more pMAA-5 and pHPMA-36 may provide us a
new angle of view to design polymeric carrier systems for renal targeting in AKI.
To quantify the amount of polymers in I/R and sham-operated kidneys and make
sure that the fluorescence observed from IVIS was from fluorescent labeled polymers,
instead of the auto-fluorescence of the tissues, plate-reader was used to detect
fluorescence in the tissue homogenates. Considering the possible auto-fluorescence from
these tissues, we analyzed these data using standard addition (Figure 5). On the basis of
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homogenized tissues, it is evident that the ratio of each polymers amount between I/R
and sham-operated kidneys was consistent with the ROI ratio from IVIS results shown
above. The highest ratio of polymers between I/R and sham-operated kidneys was
observed in pMAA-5 and pHPMA-36, which accorded with previous IVIS results.
To further understand this selective accumulation of polymers with different sizes
and charges in I/R kidney, we conducted intracellular localization and histological studies
on the both I/R and sham-operated kidney with frozen sections and H&E staining,
respectively (Figure 6). In sham-operated kidneys, even though kidneys had been exposed
to polymers, kidney tissues remained normal. For I/R kidneys, extensive tubular
dilatation and cast formation were found in cortex. According to confocal pictures, we
found in I/R and sham-operated kidneys all the 9 polymers passed glomerular filtration
barrier into Bowman space and finally can be taken up by proximal tubule cells in some
extent. The molecular weights of these polymers are less than 68 kDa which is a threshold
for macromolecules to cross this barrier. Even though basement membrane has negative
charge, it does not impact on the filtration of these polymers in either I/R or shamoperated kidneys. When getting into Bowman space, majority of positively charged
pAPMA may be susceptible to rapid renal clearance and be quickly eliminated from
kidney, while the excretion of negatively charged pMAA and neutral pHPMA from cortex
to renal pelvis might be limited in I/R kidneys [189, 192] and such polymers can be
selectively reabsorbed and sustained by renal tubule cells which are damaged during AKI.
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Figure 4. Biodistribution of pAPMA, pMAA and pHPMA in mice with unilateral I/R
injury at the indicated time points. (A) Ex vivo imaging of dissected organs at 4 or 24 h
after administration, which indicating lung, heart, liver, spleen, left kidney and right
kidney (from left to right and top to bottom). Region-of-interest (ROI) ratios of left to right
kidney (B), or ROI ratio of left kidney to liver (C) at indicated time points were quantified.
Data were shown as the mean ± SD (n = 5). **, p < 0.01.
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Figure 6. Confocal microscopy images (20X) and H&E staining (20X) of kidney sections.
Kidneys were extracted from mice with unilateral I/R injury receiving pAPMA-6,
pAPMA-16 or pAPMA-30.
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Continued Figure 6. Confocal microscopy images (20X) and H&E staining (20X) of kidney
sections. Kidneys were extracted from mice with unilateral I/R injury receiving pMAA-5,
pMAA-16 or pMAA-31.
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Continued Figure 6. Confocal microscopy images (20X) and H&E staining (20X) of kidney
sections. Kidneys were extracted from mice with unilateral I/R injury receiving pHPMA5, pHPMA-16 or pHPMA-36.
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3.4 Validation of Renal Accumulation in Bilateral I/R Kidney Injury Model
Based on previous results, we had two concerns. First, are these results reproducible?
Second, is unilateral I/R injury model comparable to bilateral renal I/R injury model in
this study? Bilateral renal I/R injury model is most frequently used in experimental study
because it is a clinically relevant model to study the AKI. However unilateral renal I/R
injury animal model provides us lots of benefits in renal accumulation study. For example,
it can avoid individual difference and reduce the risk of mortality due to the functional
redundancy [193]. To verify that our results are also applicable to bilateral I/R animal
model as well as repeat the results, we selected two polymers, pAPMA-30 and pHPMA16. We selected pAPMA-30 because we didn’t find any effect of AKI on its accumulation
in kidneys. On the contrary, pHPMA-16 in I/R kidneys was ~ 3.5 times as much as it was
in sham-operated kidneys (Figure 4B & 5H). Considering the relatively large standard
deviation in pHPMA-36 (Figure 4B), we did not select it although the variation of
fluorescence intensity between I/R and sham-operated kidneys was slightly bigger. To
evaluate renal accumulation of pAPMA-30 and pHPMA-16 in bilateral I/R animal model,
similar procedure was performed. As demonstrated in Figure 7B, a strong fluorescent
signal was observed in I/R kidneys after administration of pHPMA-16 at 4 h and it was
sustained at 24 h. Similar to the result from unilateral I/R model, pAPMA-30 showed no
preference to accumulate in the I/R kidneys at both 4 h and 24 h (Figure 7A). In addition,
compared with sham-operated kidneys, quantified fluorescence intensity of I/R kidneys
increased to ~2.1 folds and ~2.5 folds for pHPMA-16 at 4 h and 24 h, respectively, on the
basis with ROI ratio. Alteration in renal hemodynamics for unilateral and bilateral renal

55
I/R injury model might contribute to the differences in renal accumulation of pHPMA16 at 4 h. But parallel results were seen in these two animal models that polymers
potentially accumulate in I/R kidneys in unilateral renal I/R model also tend to accumulate
in I/R kidneys in bilateral renal I/R model, and vice versa. Hence, this study confirmed
our previous results and indicated that unilateral I/R animal model can be a viable model
for us to investigate renal accumulation of polymers in AKI.
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Figure 7. Biodistribution of pAPMA-30 and pHPMA-16. I/R mice or sham-operated mice
were given one injection of pAPMA-30 or pHPMA-16 at 24 h post-surgery. Ex vivo
imaging of pAPMA-30 (A) and pHPMA-16 (B) were taken at 4 h or 24 h after
administration. Organs were lung, heart, liver, spleen, left kidney and right kidney (from
left to right and top to bottom). (C) Quantified ratio of ROI between kidneys from I/R mice
and sham-operated mice. Data are shown as mean ± SD (n = 3).
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4. Conclusion
In summary, unilateral renal I/R injury model allowed us to obtain the
understanding that AKI alters renal accumulation of polymers with various sizes and
charges. Our data suggested that polymers that showed the most enhanced ability to
accumulate in I/R kidneys were negatively charged pMAA-5 and neutral pHPMA-36.
These new findings provide not only advance our fundamental understandings of
transport of polymeric drug delivery systems in normal and injured kidneys, but also
initial insights on the polymeric drug delivery systems to AKI.
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Chapter 3. Exploring the Potential of CXCR4/SDF-1 Chemokine Axis in the
Treatment of Acute Kidney Injury
1. Introduction
Acute kidney injury (AKI) is characterized by a sudden loss of renal function with
high morbidity and mortality [42, 194, 195]. AKI affects over 13 million patients
worldwide every year and remains a global public health concern [35]. It is a difficult-toprevent medical problem which involving complexed biological process, such as
vasoconstriction, leukostasis, immune activation and apoptosis [56, 196, 197]. AKI may
finally lead to chronic kidney disease and ultimately kidney failure [40], in which case the
patient would require expensive renal dialysis or transplantation [198].
As opposed to treating the damage per se, current treatment methods for AKI can
only slow down the progress of the condition. The management is mainly focused on
supportive treatment by achieving and maintaining hemodynamic stability and avoiding
hypovolemia to assure adequate renal perfusion [199]. When AKI has potentially lifethreatening complications renal replacement therapy is required [94, 95]. Several
pharmacological agents have developed on the basis of recent advances in renal injury
and repair signaling pathways, such as recombinant alkaline phosphatase, p53 siRNA and
levosimendan [98]. However, no pharmaceutical agents are successful in clinical trials so
far. Given the complex pathogenesis of AKI and lack of treatment of AKI, it might be
necessary to develop therapies that simultaneously targets multiple pathways [200].
siRNA has received increasing attention as a therapeutic approach for treating
various diseases through silencing specific genes [201-203].

Unlike other gene
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technologies, siRNAs have several unique advantages, such as high degree of
specificity to mRNAs [204], non-immunogenic property [205] and high resistance to
nucleases [206]. Several studies successfully ameliorate AKI by inhibiting gene expression
with siRNA. Kim and co-workers in the same group used hydrodynamic injection method
to inhibit Tp53-induced glycolysis and apoptosis regulator (TIGAR) expression. By doing
so, they showed renoprotective effect on ischemic kidney injury [207]. However, the
hydrodynamic injection produces high pressure during administration which will lead to
liver damage and local renal dysfunction. Therefore, this method cannot be used in large
animals and humans [208]. To safely and efficiently deliver siRNAs to kidneys, limited
studies developed carrier systems and successfully attenuated AKI. Alidori and coworkers selectively delivered siRNAs targeting both p53 and Mep1b with ammoniumfunctionalized carbon nanotube (fCNT) to renal tubule cells in AKI and the renal injury
was significantly ameliorated [136]. Yang et al. also prevented kidney damage by using
chitosan/siRNA nanoparticles targeting cyclooxygenase type 2 (COX-2) [120]. Thus, using
polymeric carrier systems to deliver siRNA in kidneys may be one of promising pathways
for therapeutic strategy for AKI.
Cytokines and chemokines are elevated in response to AKI, leading to a
proinflammatory microenvironment [157]. C-X-C chemokine receptor 4 (CXCR4) is one
of the most commonly expressed chemokine receptors in many tissues, which plays a vital
role in the process of inflammatory diseases or the metastasis in multiple types of cancers
and [162-165]. Binding with its ligand, stromal cell-derived factor-1 (SDF-1), divergent
intracellular signaling transduction pathways are initiated, which can result in a variety

60
of responses such as chemotaxis, cancer cell proliferation, recirculation and
hematopoiesis of leukocytes [166, 167]. Emerging evidence shows that the increased
chemokine receptor CXCR4 and its ligand SDF-1 are involved in the AKI pathology [164].
The CXCR4/SDF-1 axis is implicated in regulating trafficking and invasion of
inflammatory cells in the injured kidneys. The inhibition of the axis appears to exert
beneficial therapeutic effect in experimental AKI animal models [173, 175]. For example,
Yuan et al, demonstrated that the mouse renal fibrosis was attenuated after administration
of AMD3100 which is CXCR4 antagonist [175]. Therefore, interference the CXCR4/SDF-1
signaling pathway will be another promising therapeutic method for the treatment of AKI.
In this study, we report the development of a novel combinational therapeutic
strategy for treatment of AKI based on previously synthesized dual-function polymeric
CXCR4 inhibitors (PCX) which is also capable of systemically delivering siP53 to kidneys
with AKI. Our previous study suggested that PCX was able to function in such a dual
manner [209]. Here, we hypothesized that the PCX/siP53 polyplexes will lead to an
improved therapeutic effect on AKI through dual pathways of antagonizing CXCR4 and
down regulating p53.
2. Materials and Methods
2.1 Materials
Cyclam (1,4,8,11-tetraazacyclotetradecane) was obtained from Alfa Aesar (Ward
Hill, MA). N,N’-hexamethylenebisacrylamide (HMBA) was from Polysciences, Inc.
(Warrington, PA). Trifluoroacetic acid (TFA) was purchased from ACROS Organics (Fair
Lawn, NJ). RPMI 1640 medium, Dulbecco’s phosphate buffered saline (PBS), and fetal

61
bovine serum (FBS) were from Thermo Scientific (Waltham, MA). Mouse
glyceraldehyde

3-phosphate

dehydrogenase

CAGAAGACUGUGGAUGGCC

siRNA

(DTDT)-3’,

(siGAPDH

sense,

antisense,

5’5’-

GGCCAUCCACAGUCUUCUG(DGDG)-3’) were purchased from GE Healthcare
Dharmacon, Inc. (Lafayette, CO). Cyanine 3 (Cy3) NHS ester and Cyanine 5.5 (Cy5.5) NHS
ester were from Lumiprobe （Hunt Valley, MD）. Rotor-Gene SYBR Green RT-PCR Kit
was from QIAGEN (Hilden, Germany). TRIzol® reagent was purchased from Life
Technologies

(Carlsbad,

CA).

Mouse

CXCR4

primers

(Forward,

5’-

CTGTGACCGCTTCTACCCCAATGACTT-3’, Reverse, 5’-CTTGGGGTAGGAGATACG
AAAGGAACC-3’) and GAPDH primers (Forward, 5’- AACGACCCCTTCATTGAC-3’,
Reverse, 5’-TCCACG ACATACTCAGCAC-3’) were purchased from Sigma-Aldrich. The
normalized primers of phosphoglycerate kinase 1 (PGK1) (Forward, 5’-GCAGATTGTT
TGGAATGGTC-3’, Reverse, 5’-TGCTCACATGGCTGACTTTA-3’) were from Real Time
Primers. All other reagents were from Fisher Scientific and used as received unless
otherwise noted.
2.2 Methods
2.2.1 Synthesis and Characterization of PCX Polymer
The process of synthesis and characterization of PCX followed our previous
published method [209].
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2.2.2 Preparation and Characterization of PCX/siRNA Polyplexes

PCX/siRNA polyplexes were prepared in 10 mM HEPES buffer (pH 7.4) at
predetermined w/w ratios by mixing equal volume of PCX and siRNA solutions. The
polyplexes were allowed to form at room temperature for 20 min before use. Polyplexes
prepared at different PCX-to-siRNA weight ratios were loaded (20 µL of the sample
containing 1.0 µg of microRNA) and run for 30 min at 75 V in 0.5 × Tris/Borate/ EDTA
buffer. The gels were visualized under UV illumination on a KODAK Gel Logic 100
imaging system.

siRNA release from polyplexes was analyzed by heparin displacement assay. The
polyplexes were prepared at a w/w ratio of 10 and incubated with increasing
concentrations of heparin for 30 min at room temperature. The samples (20 µL of the
sample containing 0.5 µg of siRNA) were then analyzed by agarose gel electrophoresis.

Hydrodynamic diameter and ζ -potential were determined by dynamic light
scattering using a ZEN3600 Zsizer Nano-ZS (Malvern Instruments Ltd., Massachusetts,
United States). Results were expressed as mean ± standard deviation (SD) of three
experimental runs for each sample. The morphology of complexes was observed by
transmission electron microscopy (TEM, Tecnai G2 Spirit, FEI Company, USA).
2.2.3 Cellular Uptake and Intracellular Trafficking of PCX/siRNA Polyplexes
Flow cytometry analysis was used to study the cellular uptake of polyplexes. MCT
cells (105) were seeded in 12-well plates. On the other day, the cells were incubated with
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PCX/FITC-Oligo polyplexes at a FITC-Oligo concentration of 50 nM for 4 h. The cells
were then trypsinized, washed with PBS and subjected to analysis using a BD
FACSCalibur flow cytometer (BD Bioscience, Bedford, MA). The results were processed
using FlowJo software.
Intracellular trafficking was observed by LSM 800 Laser Scanning Microscope (Zeiss,
Jena, Germany). MCT cells were cultured on 24-well plates with round coverslip glass at
5 × 104 cells/well. After 24 h, a solution of polyplexes prepared at different w/w ratios was
added at FITC-Oligo concentration of 50 nM. After incubation for another 4 h, the cells
were washed twice with PBS and fixed with 4% paraformaldehyde for 10 min and nuclei
were stained with Hoechst 33258 for another 10 min.
2.2.4 Induction of Kidney Injury

To induce AKI, two different animal models were used, unilateral I/R injury and
cisplatin-induced injury. All animal experiments followed a protocol approved by the
UNMC Institutional Animal Care and Use Committee. For unilateral I/R injury, CD-1
male mice (8-10 week old) were purchased from Charles River. All animals were given
free access to food and water. The non-fluorescent food was given at least 1 week before
surgery. The mice were anesthetized by intraperitoneal administration of ketamine (200
mg/kg) and xylazine (16 mg/kg). Following left dorsal flank incision, renal pedicles were
bluntly dissected and a microvascular clamp (Roboz Surgical Instrument, Gaithersburg,
MD) was placed on the left renal pedicle for 35 min to induce unilateral I/R injury. During
the procedure, mice were kept well hydrated with warm saline and on 37 °C heating pad.
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After 35 min of occlusion, the clamps were removed and kidney reperfusion was
verified visually. Then wound clips were used to close skin. Sham-operated right side
underwent the same surgical procedure, except for the occlusion of the renal arteries. The
mice were monitored until they woke up. Cisplatin nephrotoxic AKI was induced in CD1 male mice (aged 8–10 weeks). Mice were intraperitoneally injected with a single dose of
cisplatin at 15 mg/kg after starvation for 18 h.
2.2.5 In vivo Biodistribution of Polymers
Biodistribution of the polymers in mice with cisplatin-induced injury was analyzed
by ex vivo fluorescence imaging. siRNA was labeled with Cy5.5 and PCX polymers were
labeled with Cy3. Free PCX-Cy3, free siRNA-Cy5.5 or polyplexes were administered via
tail vein injection 72 h after cisplatin administration. At 4 h and 24 h after administration
of free PCX-Cy3, free siRNA-Cy5.5 or polyplexes, mice were sacrificed and major organs
were isolated and imaged using Xenogen IVIS 200 at designated emission and excitation
wavelength. The fluorescence intensity from kidney was quantified using Living Image®
4.5

software.

The

radiant

efficiency

of

the

kidney

was

measured

as

(photons/sec/cm2/sr)/(µW/cm2). Background fluorescence was subtracted prior to analysis.
To study intracellular localization of different polymers in kidney, bisected kidneys were
embedded in OCT compound and cut into 10 µm frozen sections. The frozen sections
were either stained with DAPI, or stained with H&E. The localizations of free siRNACy5.5, free PCX-Cy3 and polyplexes were visualized by LSM 800 Laser Scanning Confocal
Microscope (Zeiss, Jena, Germany). Histopathological change was confirmed by H&E
sections under EVOS microscope.
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2.2.6 Renal Function Deterioration
Blood was collected for BUN (QuantiChromTM Urea Assay Kit, BioAssay Systems,
USA) and creatinine (QuantiChromTM Creatinine Assay Kit, BioAssay Systems, USA)
measurements. Kidneys were dissected for paraffin embedding and for qRT-PCR.
Paraffin sections (4 mm) were stained with periodic acid-Schiff (PAS) by tissue facility at
UNMC. Histopathological change was confirmed by PAS sections under EVOS
microscope.
2.2.7 RNA Isolation and Quantitative Reverse Transcription PCR (qRT-PCR)

The expression mRNA levels of CXCR4 and GAPDH were evaluated by TaqMan
qRT-PCR. Kidneys and other tissues were homogenized in TRIzol® reagent (Life
Technologies, Carlsbad, CA) according to manufacturer’s protocol for total RNA
extraction. 2 µg of total RNA was converted into cDNA using High Capacity cDNA
Reverse Transcription Kits. The obtained cDNA then served as the template for qRT-PCR
using the iTaqTM Universal SYBR Green kit (BIO-RAD) running on a Rotor-Gene Q
instrument (QIAGEN) according to the manufacturer’s instructions. mRNA expression
levels were expressed relative to the internal control according to the comparative
threshold cycle (Ct) method. Primers used for qRT-PCR amplification are specified in
Materials.
2.2.8 Statistical Analysis
Data are presented as the means ± SD. The statistical significance of the mean values
of all groups was determined by using one-way ANOVA. An unpaired t test was used to
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compare the means of two different groups. A P value < 0.05 was considered statistically
significant.
3. Results and Discussions
3.1 CXCR4 Expression in Kidneys with AKI
Chemokines are vital of importance in inflammation. They provide chemoattractive
signals for leukocytes activation and migration [210]. The increase in expression of CXCR4
in the injured kidneys has been reported by several papers [164, 211]. Here, we showed
renal CXCR4 mRNA and protein level in kidneys after unilateral I/R injury. We induced
IR injury on left kidney (I/R kidney) while the right kidney received sham surgery (healthy
kidney). At the designated time points after surgery, we conducted paraffin sections from
healthy and IR kidneys to determine the CXCR4 protein level by immunohistochemistry
analysis. The relative mRNA level was determined by qRT-PCR analysis followed by
RNA extraction. For cisplatin-induced mouse model, similar procedures were conducted
at 72 hours after cisplatin administration. The CXCR4 staining in healthy kidney showed
undetectable expression (Figure 8A), while it showed a positive patchy pattern in I/R
kidney and cisplatin injured kidney. Based on Figure 8A, we can see tubule cells are
CXCR4 positive while glomerulus is CXCR4 negative. There is more intense staining in
distal tubule compared to proximal tubule cells. H&E staining confirms the
pathophysiology of healthy and injured kidneys. Figure 8B is the relative CXCR4 mRNA
level in IR kidney and cisplatin injured kidney. For I/R kidney, CXCR4 mRNA level shows
a gradient increase along with time passing. At 1 day after surgery, the CXCR4 mRNA
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level in I/R kidney is 1.6 times as much as that in healthy kidney. At 13 days after
surgery, the CXCR4 mRNA level in I/R kidney is about 4.2 times more than that in healthy
kidney.
Based on the result of CXCR4 protein and relative mRNA level, we concluded that
the CXCR4 expression increases in the kidney with unilateral I/R animal model. The
increased CXCR4 in I/R kidney does not show obvious effect on the CXCR4 level in the
contralateral healthy kidney.
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Figure 8. Characterization of CXCR4 expression in kidney with AKI. (A) H&E staining
and CXCR4 immumostaining for healthy and I/R kidney. (B) Relative CXCR4 mRNA level
in I/R kidney. Data are shown as mean ± SD (n = 3).
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3.2 Preparation and Characterization of PCX/siRNA Polyplexes
The ability of PCX to form polyplexes with siRNA was evaluated by agarose gel
electrophoresis assay. In Figure 9A, there was a smear band at w/w ratio of 0.5 and 1. PCX
can fully condense siRNA at a w/w ratio of 2 or above as indicated by no fluorescence
signal coming out of the well. The ability of PCX/siRNA polyplexes to release siRNA was
then evaluated by heparin displacement assay (Figure 9B). For PCX/siRNA polyplexes
prepared at w/w 5, the siRNA was not fully released until the heparin concentration was
80 µg/mL, which means the polyplexes were able to release siRNA.
Hydrodynamic size and zeta-potential of PCX/siRNA polyplexes prepared at
various w/w ratios were measured by dynamic light scattering (Figure 9 C&D).
Polyplexes prepared at w/w 2 showed a relative large size with around 300 nm while the
size decreased to ~127 nm at w/w 5 and ~107 nm at w/w 10. Polydispersity indexes (PDI)
was less than 0.2 for all the three formulations. As expected, due to the redundant cationic
PCX around the surface of polyplexes, increasing the w/w ratio to make polyplexes leads
to the increased zeta-potential. The morphology of PCX/siRNA polyplexes was confirmed
by transmission electron microscopy (TEM). Nice sphere shape of PCX/siRNA polyplexes
prepared at all the three w/w ratios was observed under TEM （Figure 9E）.
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Figure 9. Characterization of polyplexes of PCX/siRNA. (A) siRNA condensation by
PCX in 10 mM HEPES buffer (pH 7.4) using agarose gel electrophoresis. (B) Heparin
induced siRNA release from the polyplexes. Polyplexes were prepared at w/w 5 and
incubated with increasing concentrations of heparin. (C) DLS size distribution of
PCX/siRNA. (D) Zeta-potential of PCX/siRNA. (E) TEM images of PCX/siRNA. Data
are shown as mean ± SD (n = 3).
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3.3 Intracellular localization and Cellular Uptake of PCX/siRNA polyplexes
To study the intracellular localization and cellular uptake, the siRNA used to form
polyplexes with PCX was labeled with FAM fluorescence. MCT cells were treated with
PCX/FAM-siRNA for 4 h followed by fixation for confocal microscopy. Cell nuclei were
stained with Hoechst 33258 which was indicated by blue color. As shown in Figure 10A,
for PCX/FAM-siRNA prepared at all the three w/w ratios, the most fluorescence of FAMsiRNA was distributed in cytoplasm while no fluorescence was observed in the cell
nucleus.
Next, we investigated the cellular uptake of PCX/siRNA polyplexes prepared at
various w/w ratios. MCT cells were incubated with the PCX/FAM-siRNA polyplexes for
4 h and cellular uptake was determined by flow cytometry. As shown in Figure 10B, the
significantly increased mean fluorescence intensity (MFI) indicated that PCX polyplexes
had significant cellular uptake in MCT cells when compared with untreated cells or cells
treated with free FAM-siRNA. The cell uptake increased when the w/w ratios in
preparation of the polyplexes increased from 2 to 10. The percentage of cells that taken up
the polyplexes (Figure 10C) showed similar trend as MFI data. PCX/siRNA polyplexes
prepared at w/w ratio of 10 were selected for subsequent in vivo study as their highest
cell uptake.
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Figure 10. Intracellular trafficking and cellular uptake of PCX/siRNA polyplexes. (A)
Intracellular trafficking of PCX/FITC-siRNA in MCT cells by confocal after 4 h of
incubation. Quantification of cellular uptake is shown by (B) mean fluorescence
intensity (MFI) and (C) % cell uptake. Data are shown as mean ± SD (n = 3).
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3.4 Biodistribution of PCX/siRNA polyplexes in vivo
Accumulation of polyplexes in focus is the prerequisite for therapeutic treatment.
Before measuring therapeutic effect of PCX/siRNA polyplexes, it is necessary to study the
biodistribution of the polyplexes in AKI mouse model.
To understand whether PCX/siRNA polyplexes can target injured kidneys, the
biodistribution of polyplexes was conducted. The mouse model we used to study
biodistribution is well-established mouse model, cisplatin-induced nephrotoxic injury. To
track polyplexes, we labeled PCX with Cy3 and siRNA with Cy5.5. Mice were sacrificed
at two designated time points, 4 h or 24 h post intravenously administration and major
organs were isolated for ex vivo fluorescence imaging by IVIS. As shown in Figure 11A, a
slightly more fluorescence of free siRNA was in healthy kidneys at 4 h after administration
and most siRNA was excreted from kidneys at 24 h after injection. On the contrary,
significant fluorescence of siRNA of polyplexes was observed in injured kidneys
compared with healthy kidneys. No obvious fluorescence was shown in other organs
except for the weak signal in liver and spleen. Quantification of fluorescence of siRNA
was shown in Figure 11B. For polyplexes, the fluorescence intensity increased
approximately by 50% in injured kidneys compared with healthy kidneys at 4 h post
injection. However, there was no difference between healthy and injured kidneys after
free siRNA administration.
As shown in Figure 11C, the PCX showed potential to accumulate in injured kidneys
for both free PCX and polyplexes. At 24 h, most PCX of polyplexes was excreted while
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free PCX remained in injured kidneys. No obvious fluorescence was shown in other
organs except for the weak signal in liver and spleen. Fluorescence quantification showed
that, at 4 h post injection, the fluorescence intensity of PCX of polyplexes in injured
kidneys was ~7 times as much as that in healthy kidney (Figure 11D).
Given the complex structure of kidney, we were further interested in suborgan
distribution of the polyplexes. To investigate the intracellular localization of PCX/siRNA
polyplexes, frozen kidney sections were visualized under confocal microscopy. As shown
in Figure 12A, most polyplexes cross glomerulus filtration barrier and accumulate in
injured mouse tubule cells at 4 h after intravenous administration. Enlarged fenestration
of filtration barrier in injured kidney may allow large polyplexes to pass through this
barrier. An alternative possibility is that polyplexes could disassemble at glomerular
basement membrane and a fraction of PCX reassociate with siRNA after filtrating into
urinary space and facilitate uptake of siRNA in tubule cells [114]. The yellow dots in
merged images indicated intact polyplexes. The ability of renal tubule cells to uptake
systemically injected siRNA has been well-known and extensively used [212, 213]. As
expected, free siRNA passed glomerulus filtration barrier and accumulated in mouse
tubule cells of both healthy and injured kidney at 4 h after intravenous administration
(Figure 12B). The intracellular localization of free PCX in kidneys was evaluated as well
(Figure 12C). Consistent with IVIS result, a lot of PCX accumulated in injured kidney
while few PCX accumulated in healthy kidney. In injured kidney, large amount of PCX
crossed glomerulus filtration barrier and distributed in tubule cells other than glomeruli
which is indicated by white arrow.
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Based on above results, we confirmed that PCX/siRNA polyplexes are able to
specifically target renal tubule cells in cisplatin-induced nephrotoxic mouse model, which
prompted us to further investigate the in vivo transfection efficacy of PCX/siRNA.
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Figure 11. Biodistribution of PCX/siRNA polyplexes in healthy mice and cisplatin-injured
mice. Ex vivo imaging of dissected organs at 4 or 24 h after administration of free siRNA
(A) and polyplexes (B). Excitation wavelength is 675 nm and emission wavelength is 720
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3.5 In vivo transfection effect of PCX/siRNA polyplexes
Silencing specific gene expression in kidneys by siRNA through systemic
hydrodynamic injection is a common method for siRNA delivery in rodents [207, 214].
Hydrodynamic injection via systemic circulation can cause transient high pressures in
veins during rapid injection of a large volume, leading to enhanced delivery of siRNA
into organs with high blood flow, such as kidneys and liver [215, 216]. Although this
method has been proven useful for a wide range of application in rodents, it is not feasible
in humans due to the possible cardiac congestion [217]. Based on above biodistribution
result of PCX/siRNA polyplexes, therefore, we will further measure silencing efficacy of
the polyplexes in vivo. We chose glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
as target gene due to its stable expression in the body. Procedure of experiment is shown
in Figure 13A. 1.67 mg/kg (50 µg) siGAPDH dose was used for hydrodynamic injection.
1.12 mg/kg (0.28 mg/kg ´ 4, free siGAPDH and w/w 5) and 0.56 mg/kg (0.14 mg/kg ´ 4,
w/w 10) siGAPDH doses were used for polyplex injections. To avoid individual difference
and reduce the risk of mortality of mice, we established a unilateral IRI model, where left
renal artery was clamped and renal injury was induced in the left kidney while the right
kidney was also exposed and remained intact. After treatment, as shown in Figure 13B,
there was approximately 25% down regulation of GAPDH mRNA in injured kidneys
treated with PCX/siGAPDH prepared at w/w 5. The silencing efficacy of PCX/siGAPDH
was slightly better than hydrodynamic injection, but the siGAPDH dose of
PCX/siGAPDH was only two thirds of the dose of hydrodynamic injection. One study
reported there was about 40% of GAPDH silencing in kidneys after hydrodynamic
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injection with an approximate siGAPDH dose of 7.5 mg/kg and other organs such as
spleen and liver also showed detectable GAPDH silencing [218]. There was no obvious
silencing for free siGAPDH although its dose was same to polyplexes prepared at w/w 5.
For polyplexes prepared at w/w 10, only about 18% down regulation of GAPDH mRNA
level due to less injected siGAPDH amount.
In summary, the polyplexes of PCX/siGAPDH prepared at w/w 5 showed a
significant GAPDH silencing in targeted injured kidney at an extremely low siGAPDH
amount. This finding is promising for further therapeutic study of polyplexes in AKI.
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Figure 13. Silencing efficacy of PCX/siGAPDH polyplexes in unilateral ischemiareperfusion mouse model. Experiment was conducted followed the procedure in (A). The
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3.6 In vivo Therapeutic Effect of PCX/siRNA Polyplexes
Results from the distribution study of PCX/siRNA complexes gave us enough
confidence to proceed to investigate the therapeutic efficacy of our formulations as a
preconditioning therapy for AKI. First, we evaluated the therapeutic efficacy of PCX only
in the cisplatin-induced animal model. As shown in Figure 14A, mice were
prophylactically treated for four consecutive days with PCX, AMD3100 or PBS. On the
third day, mice received a single nephrotoxic dose of cisplatin to induce AKI (15 mg/kg).
Blood was collected on day 4 and day 5 for renal function study. Then mice were sacrificed
on day 5 and kidneys were collected for PAS staining of paraffin sections. Based on the
level of BUN and Creatinine in Figure 14 B&C, AMD3100 and our PCX polyplexes didn’t
show any obvious nephrotoxicity in healthy mice. For mice induced AKI by cisplatin, the
BUN and Creatinine level significantly reduced after the treatment of AMD3100 and PCX,
which indicated that antagonism of CXCR4 has renoprotective effect on AKI. However,
the renal protective effect was similar between AMD3100 and our PCX polymers.
Histological analysis of kidneys from those mice was performed. PAS stained
kidneys from healthy mice receiving AMD3100 or PCX showed normal tissue
morphology. The morphology of kidneys from injured mice receiving AMD3100 or PCX
also showed consistence with healthy control mouse tissue (Figure 15A). The percentage
of damaged tubules were quantified and shown in Figure 15B.
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4. Conclusion
In summary, PCX/siRNA could be specifically delivered into injured kidney
following intravenous injection, where it can persist for about 24 h. Treatment with PCX
can mitigate AKI. And injections of very low doses of GAPDH siRNA showed similar
silencing effect to hydrodynamic injection. These data presented here provide a potential
generic platform of gene therapy for treatment of AKI and may further augment the
potential clinical application of siRNA for AKI. In the future, the pathophysiological roles
of this novel pharmacological approach will be evaluated in several proteins
overexpressed during AKI.
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Chapter 4. Conjugate polyplexes with anti-invasive properties and improved
siRNA delivery in vivo
1. Introduction
siRNA has received increasing attention as therapeutic approach for treating
various diseases through silencing specific genes [201-203]. The use of naked
unformulated siRNA, however, is associated with several inherent problems due to the
poor cellular permeability, easy degradation by endogenous enzymes and off-target
effects [149]. To efficiently deliver siRNAs to the target tissues in vivo, a wide variety of
non-viral carrier systems, such as cationic lipids and cationic polymers, have been
developed to form polyelectrolyte complexes with the oppositely charged siRNA [150,
151]. These cationic carriers provide high transfection efficiency in vitro but suffer from
low activity in vivo. The cationic carriers may not form sufficiently strong interactions with
anionic siRNA simply through electrostatic interactions because of the relatively small
size of siRNA [219, 220]. Polycations have a tendency to interact with multiple proteins in
serum and cause aggregation which can lead to fatal disseminated intravascular
coagulation-like condition [221-223]. In addition, because of their dynamic nature,
polyplexes are susceptible to disassembly by various competing biomacromolecules in
the systemic circulation or at a glomerular basement membrane in the kidneys by the
action of heparan sulfate [224-230]. Many solutions have been proposed to the premature
systemic disassembly, including modifications with hydrophobic residues and covalent
crosslinking of the particles [224, 231-233]. To overcome the limitations of siRNA in
effective electrostatic condensation with polycations, polymerized siRNA was used and

87
shown to form stable polyplexes with efficient intracellular translocation and targeted
gene silencing in vitro [234, 235]. Finally, direct covalent linkage of siRNA to synthetic
polymers can significantly improve the performance during systemic siRNA delivery
[236-238].

Human serum albumin (HSA) is the most abundant protein in human body. HSA is
involved in many important biological functions, such as delivery of nutrients from
circulating system to cells and maintenance of osmotic pressure and vascular integrity. As
a natural transport protein, HSA is able to bind with various endogenous and exogenous
molecules [239, 240]. In addition, its target specificity for glycoprotein 60 receptor, which
is presented on the surface of cancer cells, allows potential site-specific delivery of various
anti-cancer agents. Several studies also showed that albumin-based drug delivery systems
can accumulate in solid tumors and facilitate tumor targeting due to passive targeting by
enhanced permeability and retention (EPR) effect [241, 242]. Albumin has been also
explored in improving the safety and efficacy of polyplexes. Because of its negative net
charge, albumin has been utilized to coat polyplexes with the goal to avoid hepatic
accumulation, reduce toxicity and improve delivery of therapeutic nucleic acids [240, 243].
PEI/DNA polyplexes coated with albumin showed improved gene transfer efficiency with
negligible toxicity [244-246]. Stable ternary polyplexes were developed by modification of
PEI with ligands for albumin binding [247]. Interestingly, even unmodified HSA
improved the internalization and silencing efficiency of PEI/siRNA polyplexes in cancer
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cells [248]. Unfortunately, very few studies report on the use of albumin-coated
polyplexes in vivo.
CXCR4 is one of the most commonly expressed chemokine receptors, which plays
a vital role in the process of metastasis in multiple types of cancer [249]. Binding with its
ligand, stromal cell-derived

factor-1

(SDF-1), divergent

intracellular

signaling

transduction pathways are initiated, which can result in a variety of responses such as
chemotaxis, cancer cell proliferation, migration and invasion [166]. Driven by CXCR4
expressed in the primary tumor cells, the cells metastasize to secondary sites where SDF1 is highly expressed, such as lung, liver, bone marrow and brain [250]. Blocking the
CXCR4/SDF-1 interaction by antagonizing CXCR4 can inhibit macrophage infiltration,
induce tumor growth arrest and prevent metastatic spread [165, 172]. We previously
reported the synthesis of hyperbranched bioreducible polycationic CXCR4 inhibitors
named rPAMD [251-254]. The rPAMD had the ability to inhibit cancer cell invasion as a
result of their CXCR4 inhibitory activity, while mediating efficient transfection in vitro. To
further advance development of rPAMD for systemic delivery of siRNA, we hypothesized
that conjugating thiol-modified siRNA to rPAMD will enhance stability against
disassembly and that coating of such conjugates with HSA will decrease the positive
surface charge and enhance safety of the formulations (Scheme 1). Here, we have tested a
simple thiol-disulfide exchange conjugation strategy to prepare rPAMD-SS-siRNA
polyplex conjugates and tested their stability in serum and against heparin exchange.
Reporter gene silencing activity of the polyplex conjugates was tested in B16F10-luc
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mouse melanoma cells to determine how the covalent conjugation and HSA coating
affects the silencing efficacy. Finally, the systemic siRNA delivery efficacy of the
developed polyplex conjugates was tested in vivo in a syngeneic tumor model.

2. Materials and Methods
2.1 Materials
AMD3100 base form was purchased from Biochempartner (China). N,N’-cystaminebisacrylamide (CBA) was obtained from Polysciences, Inc. (Warrington, PA). Ethidium
bromide (EtBr) was from Fisher Bioreagents (Fair Lawn, N.J.). Dithiothreitol (DTT) was
obtained from Alfa Aesar (Heysham, LA3 2XY, England). Scrambled siRNA (siScr, sense:
5’-AUG AAC GUG AAU UGC UCA AUU-3’), luciferase siRNA (siLuc, sense: 5’-GGA
CGA GGA CGA GCA CUU CUU-3’), thiol-modified scrambled siRNA (siScr-SH, sense:
5’-S-S-AUG AAC GUG AAU UGC UCA AUU-3’), thiol-modified luciferase siRNA (siLucSH, sense: 5’-S-S-GGA CGA GGA CGA GCA CUU CUU-3’) were custom-synthesized by
Dharmacon, GE, and deprotected by tris(2-carboxyethyl) phosphine hydrochloride (TCEP)
solution following the manufacturer’s instructions. Dulbecco’s Modified Eagle Medium
(DMEM), RPMI-1640 Medium, Dulbecco’s Phosphate Buffered Saline (PBS), and Fetal
Bovine Serum (FBS) were from Thermo Scientific (Waltham, MA). Cell culture inserts for
24-well plates with 8.0 µm pores (Translucent PET Membrane, cat# 353097) and BD
MatrigelTM Basement Membrane Matrix (cat# 354234) were obtain from BD Biosciences
(Billerica, MA). Human SDF-1 was from Shenandoah Biotechnology, Inc. (Warwick, PA).
All other reagents were from Fisher Scientific and used as received unless otherwise noted.
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2.2 Methods
2.2.1 Synthesis and Characterization of rPAMD
rPAMD was synthesized through Michael-type polyaddition with equal molar ratio
of AMD3100 and a reducible bisacrylamide CBA [253]. Briefly, AMD3100 (100.4 mg, 0.4
mmol) and CBA (52 mg, 0.4 mmol) were dissolved in methanol/water mixture (2 mL, 7/3
v/v). The reaction was stirred under nitrogen at room temperature for 48 h. Excess
AMD3100 (10 mg) was added to react with any residual CBA acrylamide groups. After 6
h of continuous stirring, 1.25 M HCl was added dropwise to the mixture until the pH
reached 4. The resulting HCl salt of rPAMD was collected and dialyzed (molecular weight
cut-off 3.5 kDa) against acidified water (pH 4) for 3 days before final lyophilization. 1HNMR was used to confirm the chemical composition of the synthesized rPAMD and
AMD3100 content in the polymers. The completion of the reaction was validated by the
disappearance of the acrylamide peak of CBA. The weight- and number-average
molecular weights, as well as the polydispersity index (PDI, Mw/Mn) was characterized by
gel permeation chromatography (GPC) operated in 0.1 M sodium acetate buffer (pH 5.0)
using Agilent 1260 Infinity LC system equipped with a miniDAWN TREOS multi-angle
light scattering (MALS) detector and a Optilab T-rEX refractive index detector (Wyatt
Technology, Santa Barbara, CA). The column used was Tosoh Bioscience TSKgel
G3000PWXL-CP eluted at a flow rate of 0.5 mL/min. Results were analyzed using Astra
6.1 software from Wyatt Technology.
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2.2.2 Preparation and Characterization of HSA-coated Polyplexes
rPAMD/siRNA polyplexes were prepared in 5 mM HEPES buffer (pH 7.4) at
predetermined w/w ratios by mixing equal volume of rPAMD and siRNA solutions. The
polyplexes were allowed to form at room temperature for 20 min before use. Similarly,
rPAMD-SS-siRNA conjugate polyplexes were prepared by mixing of rPAMD and siRNASH in 5 mM HEPES buffer (pH 7.4) and kept at room temperature for 2 h before use. To
prepare HSA-coated polyplexes, which are named as HSA[rPAMD/siRNA] and
HSA[rPAMD-SS-siRNA], HSA solution in 5 mM HEPES buffer (pH 7.4) was added to the
prepared polyplexes or conjugate polyplexes at a HSA/rPAMD w/w ratio of 5. The
mixture was allowed to stand at room temperature for 20 min before use. Hydrodynamic
diameter and ζ-potential were determined by dynamic light scattering using a ZEN3600
Ζsizer Nano-ZS (Malvern Instruments Ltd., Massachusetts, United States). Results were
expressed as mean ± standard deviation (SD) of three experimental runs for each sample.

2.2.3 Agarose Gel Electrophoresis
Polyplexes were prepared as above and incubated with increasing concentrations of
heparin with or without 10 mM DTT. 18 µL of each sample (siRNA concentration: 20
µg/mL) were loaded onto a 2.5% agarose gel containing 0.5 µg/mL EtBr and run for 30
min under electrophoresis at 75 V in 0.5X Tris/Borate/EDTA (TBE) running buffer. Free
siRNA of the same concentration was used as the control. The gel was then visualized
under UV.
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2.2.4 Cell Culture
Human epithelial osteosarcoma U2OS cells that stably express functional EGFPCXCR4 fusion protein were obtained from Fisher Scientific and cultured in DMEM
supplemented with 2 mM L-glutamine, 1% Pen-Strep, 0.5 mg/mL G418 and 10% FBS.
Mouse melanoma cell line B16F10 expressing luciferase (B16F10-luc) was purchased from
PerkinElmer and maintained in RPMI with 10% FBS.

2.2.5 Cytotoxicity
Cytotoxicity of the polyplexes and conjugate polyplexes was determined by Cell
Titer Blue assay. The cells were plated in 96-well plates at a density of 10,000 cells/well
(B16F10-luc) and 8,000 cells/well (U2OS). The next day, the culture medium was removed
and replaced by 150 µL of serum-free medium containing polyplexes or conjugate
polyplexes prepared at w/w 2 and 5 (rPAMD concentration was 2, 8 and 15 µg/mL for
B16F10-luc cells and 2 µg/mL for U2OS cells). For B16F10-luc, the medium was replaced
with fresh growth medium after 4 h incubation and the cells were cultured for another 48
h. For U2OS, the cells were incubated with polyplexes or conjugate polyplexes for 16 h.
Then, the medium in each well was removed and a mixture of 100 µL serum-free media
and 20 µL of CellTiter-Blue reagent (CellTiter 96®Aqueous Non-Radioactive Cell
Proliferation Assay, Promega) was added. After 1 h incubation, the fluorescence (F) was
measured using Synergy 2 Microplate Reader (BioTek, VT) at an excitation wavelength of
560 nm and an emission wavelength of 590 nm. The relative cell viability (%) was
calculated as [F]sample/[F]untreated X 100%.
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2.2.6 CXCR4 Redistribution Assay
U2OS cells overexpressing EGFP-CXCR4 were plated in black 96-well plates with
optical bottom 24 h before experiment at a density of 8000 cells per well. On the day of the
assay, cells were washed twice with 100 µL assay buffer (DMEM supplemented with 2
mM L-Glutamine, 1% FBS, 1% Pen-Strep and 10 mM HEPES). Then different formulations
(2.0 µg/mL of polymer) or AMD3100 (300 nM) were added in the assay buffer containing
0.25% DMSO and incubated with cells for 30 min at 37°C. SDF-1 was then added to each
well to make the final concentration 10 nM and cells were incubated at 37°C for another 1
h. After incubation, 4% formaldehyde at room temperature for 20 min, followed by 4 times
of PBS washing and staining with 1 µM Hoechst 33258 for 30 min. Fluorescent microscopy
was conducted using EVOS fluorescence microscope (20x). High content analysis was
used to quantify the internalization of CXCR4 receptors using Cellomics ArrayScan VT1
Reader and SpotDetector V3 BioApplication software. CXCR4 inhibitory activity of 300
nM AMD3100 was considered as positive control and set as 100% and cells treated with
SDF-1 only was set as 0%. CXCR4 activity of all the tested particles was expressed as mean %
inhibition ± SD (n = 3).

2.2.7 Cell Invasion Assay
Each transwell insert was coated with 40 µL diluted ice-cold Matrigel (1:3 v/v with
serum-free medium) and placed in 37°C incubator for 2 h prior to experiment. CXCR4+
U2OS cells were trypsinized and resuspended in serum-free medium containing
AMD3100 (300 nM), rPAMD/siRNA, HSA[rPAMD/siRNA], rPAMD-SS-siRNA or
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HSA[rPAMD-SS-siRNA] (rPAMD 2.0 µg/mL). 100,000 treated cells in 300 µL medium
were added to each insert, and 20 nM SDF-1 in serum-free medium was added to the
corresponding wells in the companion plate as the chemoattractant. Cells were allowed
to invade through the Matrigel layer towards SDF-1 at 37°C for about 18 h. The noninvaded cells were then removed using a cotton swab, and the invaded cells at the bottom
of the insert were fixed with 100% methanol and stained with 0.2% Crystal Violet for 10
min. The images were taken by EVOS xl microscope (20x) and the number of invaded cells
counted in triplicate.
2.2.8 siRNA Transfection in vitro
All transfection experiments were conducted in 48-well plates using cells at their
logarithmic growth phase. B16F10-luc cells were seeded at a density of 8,000 cells/well 24
h prior to transfection. Different formulations with 100 nM siRNA were prepared as
mentioned above in 250 µL serum-free medium and then added onto cells. After 4 h
incubation, the medium was removed and replaced with fresh culture medium. Cells
were cultured for another 48 h before measuring luciferase expression. For harvesting
cells, 100 µL of 0.5x cell culture lysis buffer (Promega, Madison, WI) was added to the
cells after discarding the culture medium and then lysed for at least 20 min at room
temperature. The cell lysate was then transferred to 1.5 mL tubes and all the samples were
centrifuged at 10,000 g for 10 min at 4°C. To measure the luciferase expression, 100 µL of
0.5 mM luciferin solution was automatically injected into each well containing 20 µL of
cell lysate supernatant and the luminescence was integrated over 10 s using GloMax 96
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Microplate Luminometer (Promega). Total cellular protein in the cell lysate was
measured by the bicinchoninic acid protein assay using calibration curve constructed with
standard bovine serum albumin solutions (Pierce, Rockford, IL). Transfection activity was
expressed as % luciferase activity of siScr treated groups ± SD of triplicate samples.

2.2.9 siRNA Transfection in vivo
All animal experiments were conducted in compliance with the guidelines of the
Institutional Animal Care and Use Committee of the University of Nebraska Medical
Center. Six-week-old female C57BL/6 albino mice were subcutaneously injected with one
million B16F10-luc cells and randomized to different treatment groups to avoid cage
effects. When a tumor reached a volume of 50 mm3, the mice (in groups of 7) were injected
intravenously (i.v.) with different polyplexes or conjugate polyplexes at siRNA dose of 1
mg/kg body weight daily for 4 days. Dextrose was added into each formulation to make
a concentration of 5% before injection. The luminescence signal was detected in tumor
before and after treatment using the Perkin Elmer IVIS bioluminescence imaging system.
24 h after the last injection, all mice were sacrificed, and the tumors were harvested and
homogenized in 1x Cell Culture Lysis Reagent (Promega, Madison, WI) followed by
centrifugation at 10,000 g for 5 min. The luciferase expression was measured as described
in 2.7. Transfection activity was expressed as % luciferase expression relative to scrambled
siRNA (siScr) control groups ± SD.
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2.2.10 Statistical Analysis
Data are presented as the means ± SD. The statistical significance of the mean values
of all groups was determined by using one-way ANOVA. An unpaired t test was used to
compare the means of two different groups. A P value < 0.05 was considered statistically
significant.
3. Results and Discussions
3.1 Preparation of Albumin-coated Polyplexes and Conjugate Polyplexes
Conventional siRNA polyplexes are formed by electrostatic interactions between
polycations and the nucleic acid. One of the major challenges of these polyplexes when
applied in vivo is their stability against disassembly with competing polyelectrolytes and
other charged molecules in serum. Several viable solutions have been developed,
including covalent conjugation of siRNA to polymer carriers [237]. As part of our longterm goal to develop CXCR4-inhibiting polycations (rPAMD) for siRNA delivery, we
have adopted siRNA conjugation as a strategy to enable systemic administration of
rPAMD/siRNA

polyplexes.

We

proposed

that

assembling

the

hyperbranched

bioreducible rPAMD with 5’-thiol functionalized siRNA will lead to facile in situ
stabilization of the formed conjugate polyplexes by thiol-disulfide exchange reaction
between siRNA-SH and the abundant disulfides in rPAMD (Scheme 3). We proposed that
electrostatic interactions would dominate the initial formation of the polyplexes and that
the thiol-disulfide exchange will then proceed rapidly within the formed polyplexes
because of the local high concentration of the disulfides and thiols within the polyplexes
(Scheme 3).
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We have prepared both conventional polyplexes (rPAMD/siRNA) and conjugate
polyplexes (rPAMD-SS-siRNA) at two different polymer/siRNA w/w ratios (2 and 5). The
formation of the conjugate polyplexes was confirmed by assessing stability against
polyelectrolyte exchange with heparin (Figure 16a). While no free siRNA was observed at
any samples in the absence of heparin, the presence of as little as 60 µg/mL heparin caused
complete dissociation of the conventional polyplexes prepared at w/w 2 and in the
presence of 100 µg/mL heparin in case of polyplexes prepared at w/w 5. In contrast, the
conjugate polyplexes showed strong resistance to heparin-induced disassembly at both
w/w ratios, with only a small amount of free siRNA released by the action of heparin. The
heparin exchange assay distinguishes between electrostatically and covalently bound
siRNA. The small amount of free siRNA released from the conjugate polyplexes suggested
that not all siRNA-SH participated in the thiol-disulfide exchange, most likely because of
partial siRNA-SH oxidation. It is worth noting that the thiol-disulfide exchange may lead
to a degradation of rPAMD. The extent of the disulfide cleavage, however, depends on
the ratio of the siRNA-SH thiols to rPAMD disulfides present in the formulation. For
example, formulations prepared at w/w ratio of 5 contain ~89 disulfides for each siRNASH. We assumed that the molecular weight of siRNA-SH is about 13 600 g/mol and that
the molecular weight of the repeating unit per 1 disulfide in rPAMD is 764 g/mol. For a
typical rPAMD/siRNA-SH formulation prepared at w/w ratio of 5, that translates to about
89 disulfides per each thiol (5/764)/(1/13 600). In such a case, the extent of rPAMD cleavage
is negligible since only about 1% of the disulfides can be cleaved by the HS-siRNA.
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Successful use of any polyplex stabilization strategy requires that the stabilization
is reversible, and that siRNA is released in the cytoplasm. We have incubated the
polyplexes with 10 mM DTT to simulate intracellular reducing environment and to
confirm reversibility of the conjugate polyplexes. As shown in Figure 16a, disulfide
reduction with DTT destabilized both the polyplexes and conjugate polyplexes and
resulted in a complete release of siRNA. No differences were observed between
polyplexes prepared at the different w/w ratios.
The effect of physiological salt concentration on the integrity of the polyplexes was
investigated by incubation in PBS. High salt concentrations can weaken the electrostatic
interactions between siRNA and polycation and cause polyplex disassembly. The
destabilizing effect of PBS was clearly demonstrated in rPAMD/siRNA polyplexes by the
significant amount of released siRNA over the 24 h incubation period (Figure 16b).
Polyplexes prepared at w/w 5 were more resistant to salt dissociation than those prepared
at w/w 2. As above, the conjugate polyplexes displayed greatly enhanced stability in
physiological saline as documented by no significant siRNA release. Combination of high
ionic strength with the complex mix of proteins and other charged molecules found in
serum can further destabilize the polyplexes and so the stability was further tested in 50%
serum (FBS) (Figure 16b). As expected, conventional polyplexes disassembled rapidly in
the presence of serum and significant amount of the siRNA was degraded within 24 h as
suggested by the fading band of the free siRNA in the gel. Conjugate polyplexes showed
high stability against disassembly, although the appearance of fluorescence in the start
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well of the conjugate polyplexes at w/w 2 suggested that serum at least partially
disrupted the polyplexes structure and allowed binding of ethidium bromide to siRNA.
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Figure 16. Stability of polyplexes and conjugate polyplexes against disassembly. (a)
Heparin-induced siRNA release from the polyplexes and conjugate polyplexes prepared
at w/w ratio = 2 and 5 in 5 mM HEPES buffer (pH 7.4) and incubated with increasing
concentrations of heparin with (+) or without (-) 20 mM DTT. (b) Stability of the polyplexes
and conjugate polyplexes in 50% FBS and PBS following incubation for 0-24 h. The release
of free siRNA in both (a) and (b) was visualized by agarose gel electrophoresis. (c) Free
siRNA degradation profile in 50% FBS.
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3.2 Colloidal Characterization
Hydrodynamic size and zeta potential are important parameters that determine the
cellular uptake, pharmacokinetics and biodistribution of polyplexes. We have measured
the size and ζ potential of polyplexes and conjugate polyplexes prepared in 5 mM HEPES
(pH 7.4) at both w/w ratios by dynamic light scattering (Figure 16 and 17). Polyplexes and
conjugate polyplexes with both tested w/w ratios showed similar sizes in a range from
120-160 nm (Figure 16a) and positive ζ potentials ranging from 15 to 22 mV (Figure 17).
The size of the conjugate polyplexes was slightly larger than the sizes of the conventional
polyplexes. We have then assessed colloidal stability of both formulations by measuring
the changes in size following a 4 h incubation in PBS (Figure 16b). As expected, the
rPAMD/siRNA polyplexes showed poor colloidal stability indicated by rapid aggregation
with sizes reaching nearly 800 nm within 4 h. In contrast, the conjugate polyplexes
remained relatively stable even in PBS as their sizes increased only to 210-246 nm. When
combined with the data in Figure 16b, the improvement in colloidal stability may suggest
intra-particle crosslinking of the conjugate polyplexes by the catalytic action of the free
thiols in siRNA-SH, similar to previously reported increase in colloidal stability of
crosslinked DNA polyplexes [255].
3.3 Effect of albumin coating on polyplex properties
Both polyplex and conjugate polyplex showed highly positive surface charge, which
made them ill-suited for in vivo use. Covalent conjugation of poly(ethylene glycol) (PEG)
is the most common method to shield the positive surface charge of polyplexes. Here, we
explored alternative approach to shielding the positive surface charge by adsorption of
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HSA. Polyplexes and conjugate polyplexes were prepared as described above and then,
HSA was added and allowed to adsorb to the surface of the polyplexes (Scheme 3). We
first confirmed that HSA has no effect on polyplex stability against disassembly with
heparin, serum, or PBS (Figure 16). The polyplexes coated with HSA showed slightly
smaller hydrodynamic size in 10 mM HEPES (pH 7.4) (Figure 17a) but no effect of HSA
on colloidal stability in PBS was observed (Figure 17b). Importantly, adsorption of the
negatively charged HSA significantly decreased the ζ potential of both polyplexes and
conjugate polyplexes in solution with pH 7.4 (Figure 18), thus making them better suited
for the subsequent in vivo testing.
The HSA coating is strongly dependent on pH and because of the isoelectric point
of albumin (4.9), we predicted that the coating would be reversed during endo/lysosomal
trafficking of the polyplexes. We have thus prepared the coated polyplexes at pH 7.4 and
then decreased the pH to 5 and observed the effect of the pH change on particle size
(Figure 16c) and ζ potential (Figure 18). While the pH change had no significant effect of
the particle size, we have observed significant increase in the ζ potential for both
polyplexes and conjugate polyplexes. The ζ potential increased to the levels comparable
to those found for the non-coated polyplexes, thus strongly suggesting that HSA
dissociated from the polyplexes. Such behavior may be beneficial for the intracellular
trafficking of the polyplexes as it may lead to exposure of unmodified rPAMD/siRNA in
the endo/lysosomes and ultimately improve cytoplasmic transport.
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Figure 17. Hydrodynamic size. Polyplexes and conjugate polyplexes were prepared at
w/w ratio = 2 and 5 in 5 mM HEPES buffer (pH 7.4) and coated with HSA. Hydrodynamic
size was measured by dynamic light scattering. (a) Hydrodynamic size in 5 mM HEPES
buffer (pH 7.4); (b) Hydrodynamic size after 4 h incubation in PBS, and (c) Hydrodynamic
size after adjustment of pH from 7.4 to 5. All data shown as mean ± SD (n = 3).
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3.4 Cytotoxicity and Transfection Activity in vitro
Another important consideration for systemic siRNA delivery is to minimize
toxicity of the polyplexes. The use of bioreducible polycations such as rPAMD
substantially decreases cytotoxicity when compared with non-reducible polycations [256258]. To ensure that the formation of conjugate polyplexes and HSA coating had no
reverse effects on cytotoxicity, we evaluated the effect of polyplexes and conjugate
polyplexes on cell viability of a mouse melanoma B16F10-luc cell line (Figure 19). We have
determined cell viability at three different rPAMD concentrations: 2, 8 and 15 µg/mL and
found no significant adverse effect with any of the formulations as the cell viability
remained above 90%.
The ability of the polyplexes and conjugate polyplexes to silence expression of the
luciferase

reporter

gene

was

studied

in

B16F10-luc

cells

(Figure

20).

Oligofectamine/siRNA complexes were used as a control in all luciferase silencing studies.
Treatment with formulations prepared with negative control (siScr) showed no effect on
luciferase expression, confirming safety of the studied systems. Overall, the conjugate
polyplexes rPAMD-SS-siRNA exhibited better luciferase silencing activity than
rPAMD/siRNA polyplexes at both w/w ratios. As expected polyplexes prepared at w/w 5
showed better silencing activity than those at w/w 2. HSA coating had a small, but
significant, positive effect on the silencing activity of the conjugate polyplexes but no
effect on the activity of the conventional polyplexes. We found that HSA[rPAMD-SSsiRNA] prepared at w/w 5 showed the best luciferase silencing as they decreased the
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expression to ~45%. The best performing conjugate polyplexes showed activity fully
comparable to the Oligofectamine control.
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Figure 19. Cytotoxicity of polyplexes and conjugate polyplexes in B16F10-luc. Cells were
treated with the formulations prepared at (a) w/w 2 and (b) w/w 5. Data are shown as
mean viability ± SD (n = 3).
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3.5 CXCR4 Antagonism and Inhibition of Cancer Cell Invasion
We have developed rPAMD as antimetastatic inhibitors of the chemokine receptor
CXCR4 and it was important to validate that the conjugate polyplexes retained the
original CXCR4 inhibitory activity. First, we measured CXCR4 inhibition using CXCR4
redistribution assay by a high-content fluorescence microscopy analysis as described
previously [259, 260]. We have used a small molecule CXCR4 inhibitor AMD3100 as a
positive control and expressed the results as % of the AMD3100 activity. As shown in
Figure 21a, we have found that all tested formulations used at concentrations used in the
siRNA silencing studies showed CXCR4 inhibition indistinguishable from the activity of
300 nM AMD3100. We then investigated if the demonstrated CXCR4 inhibition resulted
in the ability of the polyplexes and conjugate polyplexes to inhibit invasion of cancer cells.
The important role of CXCR4 in the migration and invasion of multiple types of cancer
cells and the ability of CXCR4 inhibitors to prevent the migration is well known [261]. We
have previously shown that both rPAMD and rPAMD/DNA polyplexes effectively inhibit
CXCR4-mediated invasion of multiple cancer cells [254, 262]. As shown in Figure 21b, all
the polyplexes and conjugate polyplexes showed effective inhibition of cell invasion at
w/w ratio either 2 or 5. Based on the quantification of the average numbers of invaded
cells, 71% cancer cells were prevented from invading and migrating through the layer of
Matrigel by control AMD3100. The polyplexes and conjugate polyplexes achieved similar
activity as they inhibited invasion of 60-70% cancer cells. Both of the above experiments
together demonstrated that the conjugate polyplexes retain the CXCR4 activity of rPAMD.
While the mechanism of the CXCR4 inhibition by the conjugate polyplexes is not fully
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understood, we believe that excess rPAMD used in the formulations is most likely
responsible for the observed activity. Additional CXCR4 inhibition is likely contributed
as rPAMD is released and degraded in the cells following intracellular delivery and
disassembly of the conjugate polyplexes.
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Figure 21. Inhibition of CXCR4 and cancer cell invasion. (a) CXCR4 inhibition of
polyplexes and conjugate polyplexes in U2OS cells. AMD3100 (300nM) was used as a
positive control. Data are shown as mean % CXCR4 antagonism relative to AMD3100 ±
SD (n = 3). (b) Inhibition of cancer cell invasion. U2OS cells were treated with polyplexes
or conjugate polyplexes (rPAMD 2.0 µg/mL) and allowed to invade through Matrigel
upon stimulation with SDF-1 for 16 h. AMD3100 (300 nM) was used as positive control.
Data are shown as mean number of invaded cells ± SD (n = 3).
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3.6 Transfection Activity in vivo
The ability of the conjugate polyplexes to deliver siRNA systemically after
intravenous injection was investigated in mice bearing B16F10-luc tumors. We first
conducted a dose-finding and preliminary toxicity evaluation of both conventional
polyplexes and conjugate polyplexes both with and without HSA coating. We found that
coating with HSA improves safety of both formulations and increases the estimated
maximum tolerated dose about 2.5-fold (not shown). We thus focused our attention on
the HSA-coated formulations. The B16F10-luc cells were injected subcutaneously and the
tumor growth was followed by IVIS bioluminescence imaging. We have started the
treatments with HSA[rPAMD-SS-siRNA] and HSA[rPAMD/siRNA] when the tumors
reached 50 mm3. Both conjugate polyplexes and conventional polyplexes were prepared
with siLuc and siScr. The control siScr formulations were injected to establish 100%
luciferase expression levels. Following the treatments and shortly before animal sacrifice,
whole-body luminescence images were taken (Figure 22a) and luciferase expression in the
tumor regions quantified. As shown in Figure 22b, the HSA-coated conjugate polyplexes
showed increased luciferase silencing (~50%) when compared with the HSA-coated
conventional polyplexes (~30%). The tumors were resected, mechanically homogenized,
lysed and the luciferase silencing was validated in the tumor lysates as above (Figure 22c).
The tumor lysate results confirmed the superior silencing activity of the conjugate
polyplexes. The observed improved in vivo activity of the conjugate complexes confirmed
the in vitro findings and showed the importance of the polyplex stabilization for systemic
delivery. The primary benefit of coating with albumin appeared to be decrease in systemic
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toxicity most likely due to reduction in the surface charge. Potential effects of the HSA
coating on pharmacokinetics and renal clearance remain to be investigated.
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Figure 22. In vivo luciferase gene silencing by HSA-coated conjugate polyplexes. Mice
with subcutaneous B16F10-luc tumors were given daily intravenous injections for 4 days
of the HSA-coated polyplexes or conjugate polyplexes prepared with either siLuc or
control siScr. (a) Bioluminescence images of the tumor-bearing mice before sacrifice. (b)
Luciferase silencing determined from the region of interest analysis of the tumorassociated signal in live animals. Luciferase expression in animals treated with siScr was
set as 100%. (c) Luciferase silencing in homogenized tumor tissues. Data are expressed as
mean ± SEM (n = 7). * p < 0.05, ** p < 0.01.
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4. Conclusions
In conclusion, we described a simple approach to prepare polyplexes stabilized
against dissociation using in situ thiol-disulfide exchange between siRNA-SH and
bioreducible branched polycations. Our results demonstrated not only increased overall
stability of the conjugate polyplexes but also enhanced gene silencing activity in vitro and
in vivo. Further stabilization of the polyplexes by surface coating with albumin provided
additional enhancement of gene silencing in vitro and decrease of toxicity in vivo. Using
polycations that inhibit CXCR4, we confirmed that even when conjugated to the siRNA,
these polycations retain their inhibitory activity as suggested by strong ability to prevent
invasion of cancer cells. Overall, these initial findings provide impetus for further
evaluation of the conjugate polyplexes in systemic anticancer and antimetastatic siRNA
therapies. In the future, these innovative conjugate polyplexes can also be evaluated in
systemic renoprotection of AKI.

Note: Reprinted (adapted) with permission from [263]. Copyright (2018) American
Chemical Society.
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Chapter 5. Summary and Future Directions
AKI has high mortality and morbidity and remains the significant medical problem
in the world. It affects over 13 million patients worldwide every year. People who has AKI
may finally have chronic kidney disease or even ultimately kidney failure. However, there
are few effective pharmaceutical treatments to prevent AKI due to its complex
pathogenesis. It may be necessary to develop dual- or multi- functional methods to
simultaneously treat AKI. In recent years, drug targeting to the proximal tubule cells,
which are the primary injured site in AKI could provide better treatment by means of
enhancing the therapeutic efficacy of drugs and lowering unwanted side effects in other
organs. Thus, we first developed a variety of polymers with different physicochemical
properties for better understanding how those properties influence the distribution in
kidney with AKI. After we successfully synthesized pAPMA, pMAA and pHPMA with
different sizes, we found that the negatively charged pMAA-5 and neutral polymer of
pHPMA-36 showed increased accumulation in injured kidneys at 24 hours after
administration. These results confirmed that different properties of polymers have an
effect on their deposition in kidneys.
Cytokines and chemokines are elevated in response to AKI, leading to a
proinflammatory microenvironment. Emerging evidence shows that the CXCR4/SDF-1
axis is implicated in regulating trafficking and invasion of inflammatory cells in the
injured kidneys and inhibition of the axis exerts beneficial therapeutic effect in
experimental AKI animal models. siRNA has been used to successfully ameliorate AKI by
inhibiting specific gene expression through hydrodynamic injection. However, the
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hydrodynamic injection produces high pressure during administration which will lead
to liver damage and local renal dysfunction. Therefore, we developed a novel combination
therapeutic strategy for systemic treatment of AKI based on previously synthesized dualfunction polymeric CXCR4 inhibitors (PCX) capable of systemically delivering siRNA
targeting GAPDH (siGAPDH) to the kidneys with AKI. By using this polymer, we safely
and efficiently delivered siRNAs to kidneys. First, we confirmed the increase in CXCR4
level of kidney after I/R surgery. Then we demonstrated that our polymer and polyplexes
have the potential to accumulate in kidneys with cisplatin-induced AKI. For therapeutic
effect, our anti-CXCR4 polymer demonstrated renoprotective effect on cisplatin induced
AKI animals by means of inhibision of CXCR4. In addition, the polyplexes showed
increased siRNA silencing efficiency when compared with hydrodynamic injection. By
doing so, we successfully ameliorate AKI not only by siRNA silencing, but also through
interference of the CXCR4/SDF-1 signaling pathway. This method will be a promising
therapeutic way for the treatment of AKI.
Conventional siRNA polyplexes are formed by electrostatic interactions between
polycations and the nucleic acid. The cationic carriers may not form sufficiently strong
interactions with anionic siRNA simply through electrostatic interactions because of the
relatively small size of siRNA. Therefore, one of the major challenges of these polyplexes
when applied in vivo is their stability against disassembly with competing polyelectrolytes
and other charged molecules in serum. To overcome the limitations of siRNA in effective
electrostatic condensation with polycations, we tested a simple thiol-disulfide exchange
conjugation strategy to prepare rPAMD-SS-siRNA polyplex conjugates and their stability
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in serum and against heparin exchange significantly increased. Reporter gene silencing
activity of the polyplex conjugates in B16F10-luc mouse melanoma cells showed a
comparable efficiency with commercialized Oligofectamine. Finally, the systemic siRNA
delivery efficacy of the developed polyplex conjugates in vivo in a syngeneic tumor model
showed a promising silencing effect.
Our future studies will focus on drug delivery using the selected polymers that
specifically target kidneys with AKI. On the other hand, we will also improve the polyplex
formulations and on the renoprotective effect of these polyplexes in AKI. The
pathophysiological roles of the novel pharmacological dual-functional polyplexes will be
evaluated in several proteins overexpressed during AKI. Last but not the least, we will
improve survival rate of mice with AKI.
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